[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20180251854A1 - Method For Predicting Therapy Responsiveness In Basal Like Tumors - Google Patents

Method For Predicting Therapy Responsiveness In Basal Like Tumors Download PDF

Info

Publication number
US20180251854A1
US20180251854A1 US15/913,563 US201815913563A US2018251854A1 US 20180251854 A1 US20180251854 A1 US 20180251854A1 US 201815913563 A US201815913563 A US 201815913563A US 2018251854 A1 US2018251854 A1 US 2018251854A1
Authority
US
United States
Prior art keywords
nucleic acid
gene
receptor
acid molecule
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/913,563
Inventor
Ralph Markus Wirtz
Ralf Kronenwett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US15/913,563 priority Critical patent/US20180251854A1/en
Publication of US20180251854A1 publication Critical patent/US20180251854A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to methods for prediction of the therapeutic success of cancer therapy.
  • neoplastic diseases particularly gynaecological cancers like breast cancer
  • the response to neoadjuvant chemotherapy is comparatively low, with only about 20% of patients achieving pathological complete remission (pCR) with no tumor cells left in the breast or lymph nodes; the latter being the strongest prognostic factor for prolonged survival due to treatment benefit to date.
  • pCR pathological complete remission
  • ADRs severe side effects
  • chemotoxic treatments are combined with new tareted treatment options (e.g. Herceptin®, Lapatinib® and Avastin®).
  • new treatment options are related with some severe, probably life threatening side effects (e.g. cardiac toxicities upon combinatorial treatment with Herceptin®, gastrointestinal perforation upon combinatorial treatment with Avastin).
  • a better characterization of the respective tumors would thus allow a better selection of the most promising therapy in a given breast cancer patient, in order to avoid unnecessary side effects due to neoadjuvant chemotherapy in those patients which do no not draw any benefit from such therapy anyway.
  • neoplastic diseases particularly gynaecological cancers like breast cancer (BC) are characterized the fact that approximately 80% of them are estrogen receptor positive as characterized by standard immunohistochemistry, i.e. the exhibit estrogen receptors.
  • hormone ligands i.e. estrogen
  • ESR Estrogen receptors
  • the estrogen receptor is a member of the nuclear hormone family of intracellular receptors which is activated by the hormone 17- ⁇ -estradiol (estrogen).
  • the main function of the estrogen receptor is that of a DNA binding transcription factor which regulates gene expression.
  • a subfraction of estrogen receptor is able to interact with receptor tyrosine kinases (e.g. Her-2/neu) on the membrane which is critical for development of resistance towards cancer therapeutics.
  • Estrogen and the ESRs have also been implicated in breast cancer, ovarian cancer, colon cancer, prostate cancer and endometrial cancer.
  • Advanced colon cancer is associated with a loss of ER ⁇ (also termed ESR2), the predominant ESR in colon tissue, and colon cancer is treated with ER ⁇ specific agonists in some cases.
  • Estrogen receptors are overexpressed on the protein level in around 80% of breast cancer cases, referred to as “ESR positive”. Two hypotheses have been proposed to explain why this causes tumorigenesis. One stipulates that binding of estrogen to the ESR stimulates proliferation of mammary cells, with the resulting increase in cell division and DNA replication leading to mutations. The other one states that estrogen metabolism produces genotoxic waste.
  • the result of both processes is disruption of cell cycle, apoptosis and DNA repair and therefore tumor formation or growth.
  • ESR1 also termed ER ⁇
  • ER ⁇ Different versions of the ESR1 (also termed ER ⁇ ), gene have been identified (with single-nucleotide polymorphisms) and are associated with different risks of developing breast cancer.
  • ESR-positive tumors may profit from a treatment with Tamoxifen, an estrogen-receptor antagonist used as an adjuvant hormonal treatment.
  • Tamoxifen an estrogen-receptor antagonist used as an adjuvant hormonal treatment.
  • Another selective estrogen receptor modulator, raloxifene has been used as a preventative chemotherapy for women judged to have a high risk of developing breast cancer.
  • Another anti-estrogen, ICI 182,780 (Faslodex) which acts as a complete antagonist also promotes degradation of the estrogen receptor.
  • Anastrozole (Arimidex®), a drug which prevents the conversion of adrenal gland androgen hormones to estrogen, Exemestane (Aromasin®) and Letrozole (Ferrara®), which are inhibitors for the enzyme aromatase which is involved in the production of estrogen, and Megestrol acetate (Megace®) which is a progesteron agonist acting through competitive inhibition.
  • ESR1 positive tumors which clearly separate the growth characteristics and dependency on solely estrogen.
  • progesteron receptor and/or the receptor tyrosine kinase Her-2/neu. This raises e.g. the possibility of estrogen independent growth capabilities via progesterone or EGFR family ligands.
  • Estrogen receptor positive tumors do have a comparably good prognosis, while Estrogen receptor negative tumors as determined by IHC have a particularly bad prognosis.
  • tumors however, seem to demonstrate a better response towards chemotherapy, with about 20% pathological complete remission (pCR) reported.
  • pCR pathological complete remission
  • these tumors may additionally have benefit from anti-Her-2/neu regimen such as HerceptinTM or TykerbTM.
  • anti-Her-2/neu regimen such as HerceptinTM or TykerbTM.
  • bad prognosis tumors particularly bear the potential of benefit from combined antibody and chemotherapeutic regimen.
  • the worst prognosis among the breast cancer subgroups do have estrogen receptor negative, progesterone receptor negative and Her-2/neu receptor negative breast cancer, which are also the so called “basal like tumors” as originally defined by multiparametric gene array analysis by unsupervised cluster analysis (Sorlie et al., 2001)
  • a proper differentiation between these two “basal like” tumor subclasses would help to apply or develop patient or tumor specific therapies, in order to reduce side effects and improve tumor remission rates.
  • determining the expression level of a gene/protein on a non protein basis relates to methods which are not restricted to the secondary gene translation products, i.e proteins, but on other levels of the gene expression, like the mRNA, premRNA and genomic DNA structures.
  • positive receptor status and “negative receptor status” relate to the presence or absence of a given receptor, e.g. ESR, PGR or Her-2/neu, in a tissue sample. Usually, the respective status is being determined by IHC.
  • chemotherapy relates to a drug therapy which affects cell growth and cell division, i.e. which acts as a cytostatic, or which induces cell death (apoptosis). Due to their uncontrolled growth and division, cancer cells are supposed to be more affected by chemotherapy than normal cells.
  • nuclear adjuvant therapy relates to a preoperative therapy regimen consisting of a panel of hormonal, chemotherapeutic and/or antibody agents, which is aimed to shrink the primary tumour, thereby rendering local therapy (surgery or radiotherapy) less destructive or more effective, enabling breast conserving surgery and evaluation of responsiveness of tumor sensitivity towards specific agents in vivo.
  • target therapy refers to a therapy which aims at recognizing particular target molecules, which may play a role in tumor genesis or proliferation, or cell repair, for example. Such recognition may for example lead to a binding of the said target molecule, which may either enhance or decrease its activity.
  • Drugs used for such therapy comprise, among others, antibodies, particularly monoclonal antibodies, and small molecular drugs.
  • Potential targets are, for example, the EGFR receptor (which plays an important role in angiogenesis), the VEGFA ligand (likewise important for angiogenesis) or PARP1 (important for cell repair, as its inhibition makes tumors characterized by oncogene defects more susceptive to chemotherapy).
  • the EGFR receptor which plays an important role in angiogenesis
  • the VEGFA ligand likewise important for angiogenesis
  • PARP1 important for cell repair, as its inhibition makes tumors characterized by oncogene defects more susceptive to chemotherapy.
  • prediction relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (DFS, disease free survival; OAS, overall survival; DSS, Disease specific survival) of a patient, if the tumor is treated with a given therapy.
  • prognosis relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (DFS, disease free survival; OAS, overall survival; DSS, Disease specific survival) of a patient, unaffected and/or independent of the tumor treatment.
  • response marker relates to a marker which can be used to predict the clinical response and/or clinical outcome of a patient towards a given treatment.
  • carcinomas e.g., carcinoma in situ, invasive carcinoma, metastatic carcinoma
  • pre-malignant conditions neomorphic changes independent of their histological origin (e.g. ductal, lobular, medullary, mixed origin).
  • carcinomas e.g., carcinoma in situ, invasive carcinoma, metastatic carcinoma
  • pre-malignant conditions neomorphic changes independent of their histological origin.
  • carcinomas e.g., carcinoma in situ, invasive carcinoma, metastatic carcinoma
  • pre-malignant conditions neomorphic changes independent of their histological origin.
  • cancer is not limited to any stage, grade, histomorphological feature, invasiveness, agressivity or malignancy of an affected tissue or cell aggregation.
  • stage 0 cancer stage I cancer, stage II cancer, stage III cancer, stage IV cancer, grade I cancer, grade II cancer, grade III cancer, malignant cancer, primary carcinomas, and all other types of cancers, malignancies and transformations associated with the lung, ovar, cervix, endometrium, esophagus, stomach, pancreas, prostate, head and neck, renal cell, liver, colorectal or breast cancer are included.
  • Particularly types of adenocarcinoma are included, as well as all carcinomas of unknown primary (cup-syndromes).
  • neoplastic lesion or “neoplastic disease” or “neoplasia” or “cancer” are not limited to any tissue or cell type they also include primary, secondary or metastatic lesions of cancer patients, and also comprises lymph nodes affected by cancer cells or minimal residual disease cells either locally deposited (e.g. bone marrow, liver, kidney) or freely floating throughout the patient's body.
  • neoplastic cells refer to abnormal cells that grow by cellular proliferation more rapidly than normal.
  • neoplastic cells of the invention may be cells of a benign neoplasm or may be cells of a malignant neoplasm.
  • the term “characterizing the state of a neoplastic disease” is related to, but not limited to, measurements and assessment of one or more of the following conditions: Type of tumor, histomorphological appearance, dependence on external signal (e.g. hormones, growth factors), invasiveness, motility, state by TNM (2) or similar, agressivity, malignancy, metastatic potential, and responsiveness to a given therapy.
  • Her-2/neu relates to a gene encoding for a cell signalling protein. Synonyms for this gene are “ErbB” or “ERBB”. The three terms are being used interchangeably in this specification.
  • biological sample refers to a sample obtained from a patient.
  • the sample may be of any biological tissue or fluid.
  • samples include, but are not limited to, sputum, blood, serum, plasma, blood cells (e.g., white cells), circulating cells (e.g. stem cells or endothelial cells in the blood, tissue, core or fine needle biopsy samples, cell-containing body fluids, free floating nucleic acids, urine, stool, peritoneal fluid, and pleural fluid, liquor cerebrospinalis, tear fluid, or cells there from.
  • Biological samples may also include sections of tissues such as frozen or fixed sections taken for histological purposes or microdissected cells or extracellular parts thereof.
  • a biological sample to be analyzed is tissue material from a neoplastic lesion taken by aspiration or punctuation, excision or by any other surgical method leading to biopsy or resected cellular material.
  • a biological sample may comprise cells obtained from a patient. The cells may be found in a cell “smear” collected, for example, by a nipple aspiration, ductal lavarge, fine needle biopsy or from provoked or spontaneous nipple discharge.
  • the sample is a body fluid.
  • Such fluids include, for example, blood fluids, serum, plasma, lymph, ascitic fluids, gynecological fluids, or urine but not limited to these fluids.
  • the term “therapy modality”, “therapy mode”, “regimen” or “chemo regimen” as well as “therapy regimen” refers to a timely sequential or simultaneous administration of anti-tumor, and/or anti vascular, and/or anti stroma, and/or immune stimulating, and/or blood cell proliferative agents, and/or radiation therapy, and/or hyperthermia, and/or hypothermia for cancer therapy.
  • the administration of these can be performed in an adjuvant and/or neoadjuvant mode.
  • the composition of such “protocol” may vary in the dose of each of the single agents, timeframe of application and frequency of administration within a defined therapy window.
  • array or “matrix” an arrangement of addressable locations or “addresses” on a device is meant.
  • the locations can be arranged in two dimensional arrays, three dimensional arrays, or other matrix formats.
  • the number of locations can range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site.
  • Arrays include but are not limited to nucleic acid arrays, protein arrays and antibody arrays.
  • a “nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides, nucleotide analogues, polynucleotides, polymers of nucleotide analogues, morpholinos or larger portions of genes.
  • the nucleic acid and/or analogue on the array is preferably single stranded.
  • Arrays wherein the probes are oligonucleotides are referred to as “oligonucleotide arrays” or “oligonucleotide chips.”
  • a “microarray,” herein also refers to a “biochip” or “biological chip”, an array of regions having a density of discrete regions of at least about 100/cm 2 , and preferably at least about 1000/cm 2 .
  • the regions in a microarray have typical dimensions, e.g., diameters, in the range of between about 10-250 ⁇ m, and are separated from other regions in the array by about the same distance.
  • a “protein array” refers to an array containing polypeptide probes or protein probes which can be in native form or denatured.
  • An “antibody array” refers to an array containing antibodies which include but are not limited to monoclonal antibodies (e.g. from a mouse), chimeric antibodies, humanized antibodies or phage antibodies and single chain antibodies as well as fragments from antibodies.
  • small molecule is meant to refer to a compound which has a molecular weight of less than about 5 kD and most preferably less than about 4 kD.
  • Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic (carbon-containing) or inorganic molecules.
  • Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention to identify compounds that modulate a bioactivity.
  • modulated or modulation or regulated or regulation and “differentially regulated” as used herein refer to both upregulation [i.e., activation or stimulation, e.g., by agonizing or potentiating] and down regulation [i.e., inhibition or suppression, e.g., by antagonizing, decreasing or inhibiting].
  • transcriptome relates to the set of all messenger RNA (mRNA) molecules, or “transcripts”, produced in one or a population of cells. Importantly, this term includes also non-translated RNAs such as “micro RNA's”, which affect cellular characteristics because of gene regulation functions (silencing or activation or stabilization or degradation of other genes and transcripts). The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. Unlike the genome, which is roughly fixed for a given cell line (excluding mutations), the transcriptome can vary with external environmental conditions.
  • transcriptome Because it includes all RNA transcripts in the cell, the transcriptome reflects the genes that are being actively expressed at any given time, with the exception of mRNA degradation phenomena such as transcriptional attenuation. It also includes posttranscriptional events such as alternative splicing.
  • the discipline of transcriptomics examines the expression level of mRNAs in a given cell population, often using high-throughput techniques based on DNA microarray technology.
  • expression levels refers, e.g., to a determined level of gene expression.
  • pattern of expression levels refers to a determined level of gene expression compared either to a reference gene (e.g. housekeeper or inversely regulated genes) or to a computed average expression value (e.g. in DNA-chip analyses).
  • a pattern is not limited to the comparison of two genes but is more related to multiple comparisons of genes to reference genes or samples.
  • a certain “pattern of expression levels” may also result and be determined by comparison and measurement of several genes disclosed hereafter and display the relative abundance of these transcripts to each other.
  • a differentially expressed gene disclosed herein may be used in methods for identifying reagents and compounds and uses of these reagents and compounds for the treatment of cancer as well as methods of treatment.
  • the differential regulation of the gene is not limited to a specific cancer cell type or clone, but rather displays the interplay of cancer cells, muscle cells, stromal cells, connective tissue cells, other epithelial cells, endothelial cells of blood vessels as well as cells of the immune system (e.g. lymphocytes, macrophages, killer cells).
  • a “reference pattern of expression levels”, within the meaning of the invention shall be understood as being any pattern of expression levels that can be used for the comparison to another pattern of expression levels.
  • a reference pattern of expression levels is, e.g., an average pattern of expression levels observed in a group of healthy or diseased individuals, serving as a reference group.
  • Primer pairs and “probes”, within the meaning of the invention, shall have the ordinary meaning of this term which is well known to the person skilled in the art of molecular biology.
  • “primer pairs” and “probes”, shall be understood as being polynucleotide molecules having a sequence identical, complementary, homologous, or homologous to the complement of regions of a target polynucleotide which is to be detected or quantified.
  • nucleotide analogues and/or morpholinos are also comprised for usage as primers and/or probes.
  • “Individually labeled probes”, within the meaning of the invention, shall be understood as being molecular probes comprising a polynucleotide, oligonucleotide or nucleotide analogue and a label, helpful in the detection or quantification of the probe.
  • Preferred labels are fluorescent molecules, luminescent molecules, radioactive molecules, enzymatic molecules and/or quenching molecules.
  • arrayed probes within the meaning of the invention, shall be understood as being a collection of immobilized probes, preferably in an orderly arrangement.
  • the individual “arrayed probes” can be identified by their respective position on the solid support, e.g., on a “chip”.
  • tumor response refers, in the adjuvant chemotherapeutic setting to the observation of a defined tumor free or recurrence free survival time (e.g. 2 years, 4 years, 5 years, 10 years). This time period of disease free survival may vary among the different tumor entities but is sufficiently longer than the average time period in which most of the recurrences appear.
  • response may be monitored by measurement of tumor shrinkage and regression due to apoptosis and necrosis of the tumor mass.
  • recurrence or “recurrent disease” includes distant metastasis that can appear even many years after the initial diagnosis and therapy of a tumor, or local events such as infiltration of tumor cells into regional lymph nodes, or occurrence of tumor cells at the same site and organ of origin within an appropriate time.
  • Prediction of recurrence does refer to the methods described in this invention. Wherein a tumor specimen is analyzed for it's gene expression and furthermore classified based on correlation of the expression pattern to known ones from reference samples. This classification may either result in the statement that such given tumor will develop recurrence and therefore is considered as a “non responding” tumor to the given therapy, or may result in a classification as a tumor with a prolonged disease free post therapy time.
  • Bioactivity or “bioactivity” or “activity” or “biological function”, which are used interchangeably, herein mean an effector or antigenic function that is directly or indirectly exerted by a polypeptide (whether in its native or denatured conformation), or by any fragment thereof in vivo or in vitro.
  • Biological activities include but are not limited to binding to polypeptides, binding to other proteins or molecules, enzymatic activity, signal transduction, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc.
  • a bioactivity can be modulated by directly affecting the subject polypeptide.
  • a bioactivity can be altered by modulating the level of the polypeptide, such as by modulating expression of the corresponding gene.
  • marker refers to a biological molecule, e.g., a nucleic acid, peptide, protein, hormone, etc., whose presence or concentration can be detected and correlated with a known condition, such as a disease state.
  • ligand relates to a molecule that is able to bind to and form a complex with a biomolecule to serve a biological purpose. In a narrower sense, it is an effector molecule binding to a site on a target protein, by intermolecular forces such as ionic bonds, hydrogen bonds and Van der Waals forces.
  • the docking (association) is usually reversible (dissociation).
  • Actual irreversible covalent binding between a ligand and its target molecule is rare in biological systems.
  • Ligand binding to receptors often alters the chemical conformation, i.e. the three dimensional shape of the receptor protein. The conformational state of a receptor protein determines the functional state of a receptor. The tendency or strength of binding is called affinity.
  • Ligands include substrates, inhibitors, activators, and neurotransmitters.
  • agonist relates to a substance that binds to a specific receptor and triggers a response in the cell. It mimics the action of an endogenous ligand that binds to the same receptor.
  • receptor relates to a protein on the cell membrane or within the cytoplasm or cell nucleus that binds to a specific molecule (a ligand), such as a neurotransmitter, hormone, or other substance, and initiates the cellular response to the ligand.
  • a ligand such as a neurotransmitter, hormone, or other substance
  • signalling pathway is related to any intra- or intercellular process by which cells converts one kind of signal or stimulus into another, most often involving ordered sequences of biochemical reactions out- and inside the cell, that are carried out by enzymes and linked through hormones and growth factors (intercellular), as well as second messengers (intracellular), the latter resulting in what is thought of as a “second messenger pathway”.
  • intercellular hormones and growth factors
  • intracellular second messengers
  • the number of proteins and other molecules participating in these events increases as the process emanates from the initial stimulus, resulting in a “signal cascade” and often results in a relatively small stimulus eliciting a large response.
  • marker gene refers to a differentially expressed gene whose expression pattern may be utilized as part of a predictive, prognostic or diagnostic process in healthy conditions, premalignant disease status, malignant neoplasia or cancer evaluation, or which, alternatively, may be used in methods for identifying compounds useful for the treatment or prevention of malignant neoplasia and head and neck, colon or breast cancer in particular.
  • a marker gene may also have the characteristics of a target gene.
  • Target gene refers to a differentially expressed gene involved in cancer or pre-cancerous lesions, e.g., lung, head and neck, colon, ovarian or breast cancer in a manner in which modulation of the level of the target gene expression or of the target gene product activity may act to ameliorate symptoms of malignant neoplasia and lung, liver, endometrium, ovarian, cervix, esophagus, stomach, pancreas, prostate, head and neck, renal cell, colorectal or breast cancer in particular.
  • a target gene may also have the characteristics of a marker gene.
  • expression level relates to each step within the process by which a gene's DNA sequence is converted into functional protein (i.e. ligands) via RNA intermediates and particularly to the amount of said conversion.
  • hybridization based method refers to methods imparting a process of combining complementary, single-stranded nucleic acids or nucleotide analogues into a single double stranded molecule. Nucleotides or nucleotide analogues will bind to their complement under normal conditions, so two perfectly complementary strands will bind to each other readily. In bioanalytics, very often labeled, single stranded probes are in order to find complementary target sequences. If such sequences exist in the sample, the probes will hybridize to said sequences which can then be detected due to the label. Other hybridization based methods comprise microarray and/or biochip methods.
  • probes are immobilized on a solid phase, which is then exposed to a sample. If complementary nucleic acids exist in the sample, these will hybridize to the probes and can thus be detected.
  • array based methods Yet another hybridization based method is PCR, which is described below. When it comes to the determination of expression levels, hybridization based methods may for example be used to determine the amount of mRNA for a given gene.
  • Serial analysis of gene expression is a method for comprehensive analysis of gene expression patterns, which is based on the facts that (i) a short sequence tag (10-14 bp) contains sufficient information to uniquely identify a transcript provided that that the tag is obtained from a unique position within each transcript; (ii) sequence tags can be linked together to from long serial molecules that can be cloned and sequenced; and (iii) quantitation of the number of times a particular tag is observed provides the expression.
  • a PCR based method refers to methods comprising a polymerase chain reaction (PCR). This is a method of exponentially amplifying nucleic acids, e.g. DNA by enzymatic replication in vitro. As PCR is an in vitro technique, it can be performed without restrictions on the form of DNA, and it can be extensively modified to perform a wide array of genetic manipulations. When it comes to the determination of expression levels, a PCR based method may for example be used to detect the presence of a given mRNA by (1) reverse transcription of the complete mRNA pool (the so called transcriptome) into cDNA with help of a reverse transcriptase enzyme, and (2) detecting the presence of a given cDNA with help of respective primers. This approach is commonly known as reverse transcriptase PCR (rtPCR).
  • rtPCR reverse transcriptase PCR
  • PCR-based methods comprise e.g. real time PCR, and, particularly suited for the analysis of expression levels, kinetic or quantitative PCR (qPCR).
  • Quantitative real-time PCR refers to any type of a PCR method which allows the quantification of the template in a sample.
  • Quantitative real-time PCR comprise different techniques of performance or product detection as for example the TaqMan technique or the LightCycler technique.
  • the TaqMan technique for examples, uses a dual-labelled fluorogenic probe.
  • the TaqMan real-time PCR measures accumulation of a product via the fluorophore during the exponential stages of the PCR, rather than at the end point as in conventional PCR.
  • the exponential increase of the product is used to determine the threshold cycle, CT, i.e.
  • the set up of the reaction is very similar to a conventional PCR, but is carried out in a real-time thermal cycler that allows measurement of fluorescent molecules in the PCR tubes.
  • a probe is added to the reaction, i.e., a single-stranded oligonucleotide complementary to a segment of 20-60 nucleotides within the DNA template and located between the two primers.
  • a fluorescent reporter or fluorophore e.g., 6-carboxyfluorescein, acronym: FAM, or tetrachlorofluorescin, acronym: TET
  • quencher e.g., tetramethylrhodamine, acronym: TAMRA, of dihydrocyclopyrroloindole tripeptide “minor groove binder”, acronym: MGB
  • the 5′ to 3′ exonuclease activity of the Taq polymerase degrades that proportion of the probe that has annealed to the template (Hence its name: Taq polymerase+PacMan). Degradation of the probe releases the fluorophore from it and breaks the close proximity to the quencher, thus relieving the quenching effect and allowing fluorescence of the fluorophore. Hence, fluorescence detected in the real-time PCR thermal cycler is directly proportional to the fluorophore released and the amount of DNA template present in the PCR.
  • planar waveguide relates to detection chips and chambers for performing multiplex PCR assays, as for example disclosed in WO2007059423, which has been filed by the applicant of the present invention and which is incorporated herein by reference.
  • planar waveguides may be used in methods of performing a multiplex polymerase chain reaction (PCR) assay with a single fluorogenic dye.
  • PCR polymerase chain reaction
  • determining the protein level refers to methods which allow the quantitative and/or qualitative determination of one or more proteins in a sample. These methods include, among others, protein purification, including ultracentrifugation, precipitation and chromatography, as well as protein analysis and determination, including the use protein microarrays, two-hybrid screening, blotting methods including western blot, one- and two dimensional gel electrophoresis, isoelectric focusing as well as methods being based mass spectrometry like MALDI-TOF and the like.
  • the term “method based on the electrochemical detection of molecules” relates to methods which make use of an electrode system to which molecules, particularly biomolecules like proteins, nucleic acids, antigens, antibodies and the like, bind under creation of a detectable signal. Such methods are for example disclosed in WO0242759, WO0241992 and WO02097413 filed by the applicant of the present invention, the content of which is incorporated by reference herein.
  • These detectors comprise a substrate with a planar surface which is formed, for example, by the crystallographic surface of a silicon chip, and electrical detectors which may adopt, for example, the shape of interdigital electrodes or a two dimensional electrode array.
  • These electrodes carry probe molecules, e.g.
  • nucleic acid probes capable of binding specifically to target molecules, e.g. target nucleic acid molecules.
  • the probe molecules are for example immobilized by a Thiol-Gold-binding.
  • the probe is modified at its 5′- or 3′-end with a thiol group which binds to the electrode comprising a gold surface.
  • target nucleic acid molecules may carry, for example, an enzyme label, like horseradish peroxidise (HRP) or alkaline phosphatase.
  • HRP horseradish peroxidise
  • alkaline phosphatase alkaline phosphatase
  • a substrate is then added (e.g., ⁇ -naphthyl phosphate or 3,3′5,5′-tetramethylbenzidine which is converted by said enzyme, particularly in a redox-reaction.
  • the product of said reaction, or a current generated in said reaction due to an exchange of electrons, can then be detected with help of the electrical detector in a site specific manner.
  • anamnesis relates to patient data gained by a physician or other healthcare professional by asking specific questions, either of the patient or of other people who know the person and can give suitable information (in this case, it is sometimes called heteroanamnesis), with the aim of obtaining information useful in formulating a diagnosis and providing medical care to the patient. This kind of information is called the symptoms, in contrast with clinical signs, which are ascertained by direct examination.
  • the term “etiopathology” relates to the course of a disease, that is its duration, its clinical symptoms, and its outcome.
  • detection of a ligand and/or receptor means both the qualitative detection of the presence of the respective gene as well as the quantitative detect detection of the expression level of the respective gene, e.g. by quantitative reverse transcriptase PCR.
  • nucleic acid molecule is intended to indicate any single- or double stranded nucleic acid molecule comprising DNA (cDNA and/or genomic DNA), RNA (preferably mRNA), PNA, LNA and/or Morpholino.
  • stringent conditions relates to conditions under which a probe will preferably hybridize to its target subsequence and much less to other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at Tm, 50% of the probes are occupied at equilibrium).
  • Tm thermal melting point
  • stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g. 10 to 50 nucleotides) and at least about 60° C. for longer probes. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide and the like.
  • fragment of the nucleic acid molecule is intended to indicate a nucleic acid comprising a subset of a nucleic acid molecule according to one of the claimed sequences. The same is applicable to the term “fraction of the nucleic acid molecule”.
  • nucleic acid molecule refers herein to a nucleic acid molecule which is substantially similar in structure and biological activity to a nucleic acid molecule according to one of the claimed sequences.
  • homologue of the nucleic acid molecule refers to a nucleic acid molecule the sequence of which has one or more nucleotides added, deleted, substituted or otherwise chemically modified in comparison to a nucleic acid molecule according to one of the claimed sequences, provided always that the homologue retains substantially the same binding properties as the latter.
  • derivative refers to a nucleic acid molecule that has similar binding characteristics to a target nucleic acid sequence as a nucleic acid molecule according to one of the claimed sequences.
  • sequence identity of at least X % refers to a sequence identity as determined after a sequence alignment carried out with the family of BLAST algorithms as accessible on the respective Internet domain provided by NCBI.
  • the disclosed method can be used to select chemotherapeutic and/or antibody based regimen for breast cancers exhibiting reduced estrogen receptor expression on RNA and or/protein level.
  • a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment comprising the steps of:
  • FIG. 1 shows results of an Affymetrix array analysis (HG U133A) in fresh tissue biopsies or RT-kPCR analysis in fixed tissue biopsies of high risk breast tumors.
  • HG U133A Affymetrix array analysis
  • FIG. 2 shows identification of the basa-like subtypes based on 2D hierarchial clustering.
  • FIG. 3 shows a Kaplan Meyer curve in which, for the different groups determined as above (see Example 3, the overall survival time (OAS) is plotted versus the respective percentage.
  • FIG. 4 shows a Kaplan Meyer curve in which, for the different groups determined as above (see Example 3, the overall survival time (OAS) is plotted versus the respective percentage.
  • a deviating expression level of either of the aformentioned genes can have different reasons, these being
  • the at least one gene of interest is correlated with a negative Estrogen receptor status.
  • the applicants have, in various studies, analyzed breast tumors with ESR1 negative and Her-2/neu negative status as determined with Immunochistochemistry (IHC) and/or Fluorescence In situ Hybridization (FISH). Core needle biopsy specimen of these tumors was analyzed on the DNA and RNA level by quantitative PCR, RT-PCR and array technologies.
  • IHC Immunochistochemistry
  • FISH Fluorescence In situ Hybridization
  • ESR1 positive tumors IHC status 4, i.e. ESR status as determined with Immunohistochemistry
  • ESR1 negative tumors IHC status 0
  • MapLocation, LocusLink, Unigene and OMIM relate to databases in which the respective proteins are listed under the given access number. These databases can be accessed over the NCBI server.
  • Genes related to growth factor signalling may for example encode for hormone receptors, growth factor receptors, growth factor ligands, inhibitors and the like.
  • Such genes comprise, for example, genes encoding a receptor from the ErbB-family, or a gene correlated with the Progesterone receptor (PGR) status in the said sample.
  • PGR Progesterone receptor
  • Genes related to immune cell infiltration may be selected from the following table (listing is not exclusive):
  • basal markers are derived from the appearance of the respective cells, which is similar to basal cells.
  • MMP1, MLPH, ESR1 and Her-2/neu are subject of a most preferred embodiment of the invention.
  • At least one mode of treatment for which prediction is sought is a neoadjuvant chemotherapy and/or targeted therapy.
  • ESR negative (ESR ⁇ ) tumors which are not susceptible to endocrine treatment with, for example, tamoxifen.
  • Said chemotherapy may comprise the administration of at least one agent selected from the group consisting of Cyclophosphamid (Endoxan®, Cyclostin®).
  • Adriamycin Doxorubicin
  • BCNU Carmustin
  • Busulfan Myleran®
  • Bleomycin Bleomycin®
  • Carboplat® Chlorambucil
  • Leukeran® Cis-Platin
  • Platinex Platinum
  • DTIC® Detimedac®
  • Docetaxel Taxotere®
  • Epirubicin Flumorubicin®
  • Etoposid Etoposid
  • Vepesid® 5-Fluorouracil
  • Fluorouracil® Fluorouracil®
  • Gemcitabin Gamzar®
  • Ifosfamid Holoxan®
  • Interferon alpha Roferon®
  • BRCA1 breast cancer 1, early onset
  • BRCA1 belongs to a class of genes known as tumor suppressors, which maintain genomic integrity to prevent uncontrolled proliferation.
  • the multifactorial BRCA1 protein product is involved in DNA damage repair, ubiquitination, transcriptional regulation as well as other functions.
  • Genetic variations leading to a BRCA1 deficiency have been implicated in a number of hereditary cancers, namely breast, ovarian and prostate, as an important DNA repair system is lost which otherwise would prevent the accumulation of mutations fostering tumor genesis.
  • BRCA1 Genetic variations of BRCA1 comprise, for example, (i) an altered methylation pattern, (ii) a mutation in the gene (i.e. SNP or gene rearrangements), or (iii) an alteration of the respective promoter.
  • BRCA1 deficient tumors are known to be quickly growing tumors which are comparatively resistant against chemotherapy.
  • a novel treatment for these tumors is inhibitors of Poly (ADP-ribose) polymerase 1 (PARP1).
  • PARP1 plays a role in repair of single-stranded DNA (ssDNA) breaks.
  • ssDNA single-stranded DNA
  • dsDNA double-strand DNA
  • HR homologous recombination
  • HR pathway If the HR pathway is functioning, PARP1 deficient mutants do not show an unhealthy phenotype.
  • BRCA1 is necessary for the HR pathway to work properly. Therefore, cells which are deficient in BRCA1 are highly sensitive to PARP1 inhibition or knock-down, resulting in cell death by apoptosis, in stark contrast to cells with at least one functionally intact copy of BRCA1.
  • BRCA1 deficient mutants are likely to become prone to apoptosis in case they are also deficient for PARP1, or PARP1 is inhibited by a respective drug, i.e. a PARP1 inhibitor (see above); preferably if the latter is combined with chemotherapy, e.g. taxane administration.
  • a respective drug i.e. a PARP1 inhibitor (see above); preferably if the latter is combined with chemotherapy, e.g. taxane administration.
  • PARP1 inhibition therapy is a promising treatment for BRCA1 deficient tumors.
  • the inventors found that simultaneous detection of MMP7 and/or MLPH reveals as well the latter variants discussed above (i.e. variant (i) and (iii), and will thus help to provide adequate treatment for those patients which have a BRCA1 deficiency that is not caused by mutation of the BRCA1 gene itself.
  • the inventors estimate that, by the said simultaneous detection of MMP7 and/or MLPH, between 2 to 5 times more BRCA1 deficient tumors can be detected than with the current tests, which means that up to 5 times more patients can be provided with adequate PARP1 inhibition treatment.
  • RB1 Retinoblastoma 1
  • MMP7 positive tumors were frequently found to have decreased expression of RB1 (Retinoblastoma 1), i.e. there seems to be a correlation between MMP7 overexpression and RB1 deficiency.
  • RB1 is not only a negative regulator of the cell cycle (indeed, it has been the first tumor suppressor gene identified), but also involved in the stabilization of constitutive chromatin.
  • RB1 deficient tumors are particularly sensitive towards intensified chemotherapy and also inclusion of PARP1 inhibitors, namely for the same reasons as mentioned in the context of BRCA1.
  • PARP1 inhibition and addition of taxanes is beneficial in these tumors, which otherwise have a poor outcome.
  • BRCA1 direct determination of the expression level of RB1 is complex, as the median expression level of RB1 is downregulated by approximately 2 fold, which is in the range of assay variabilities for some gene expression determination methods (e.g. RT-PCR), and is highly dependent on the share of tumor cells in the respective sample.
  • RT-PCR gene expression determination methods
  • CCND1 Cyclin D1 (PRAD1).
  • the CCND1 protein contributes to the progression of the cell cycle in the G1/S checkpoint.
  • CCND1 overexpression (for instance as a consequence of CCND1 amplification) might result in loss of control over genetic damage at this point and in an accumulation of chromosomal aberrations.
  • the said genes are listed in the following table:
  • the mode of treatment for which prediction is sought is a therapy directed to the inhibition of homologous recombination repair.
  • This is, for example, being done be determination of MMP7 and/or MLPH, which are reciprocally correlated with RB1, BRCA1 and CCND1.
  • MMP7 and/or MLPH are reciprocally correlated with RB1, BRCA1 and CCND1.
  • a high expression level of MMP7 and/or MLPH is an indication for a therapy directed to the inhibition of homologous recombination repair.
  • PARP1 Poly (ADP-ribose) polymerase 1
  • PARP1 ADP-ribose polymerase 1
  • AZD2281 KU-0059436
  • FR247304 AG14361
  • GPI 15427 GPI 16539
  • caffeine metabolites like 1,7-dimethylxanthine, 3-methylxanthine 1-methylxanthine, theobromine and theophylline, and others.
  • the method further comprises the steps of
  • EGFR expression is particularly prominent in tumors exhibiting low expression of Her-2/neu, ESR1 and PGR.
  • the exact and robust determination of EGFR expression is critical both on protein and mRNA level. It is particularly difficult to determine a clear cut threshold to reliably discriminate between high and low expressing breast tumors, in part because of a narrow dynamic range of EGFR expression and technical variations due to assay platform or variable tissue composition in independent tumor samples of the same tumor.
  • MMP7 is robust and more reliable, as the dynamic range is broader and the data distribution is almost bimodal, enabling to define a biologically and clinically meaningful threshold between high and low expressing tumors.
  • ESR ErbB pathway
  • MAPKs ERK1 and ERK2 which are downstream components of the Her-2/neu signalling pathway, the latter being a member of the ErbB receptor family.
  • Genes related to growth factor signalling may for example encode for growth factor receptors, growth factor ligands, inhibitors and the like.
  • tumors demonstrating elevated expression levels of MMP1 and low and/or undetectable MLPH levels belong to the group of “basal-like tumors” exhibiting low expression of ESR1 and Her-2/neu, but yet having a high risk if not treated by chemotherapy regimen.
  • Particularly preferred at least one of the receptors the expression level of which is determined is Her-2/neu.
  • Her-2/neu (also known as ErbB-2, ERBB2) is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. Her-2/neu is notable for its role in the pathogenesis of breast cancer and as a target of treatment. It is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. Her-2/neu is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. However, ErbB receptors dimerize on ligand binding, and Her-2/neu is the preferential dimerization partner of other members of the ErbB family. The Her-2/neu gene is a proto-oncogene located at the long arm of human chromosome 17 (17q11.2-q12).
  • breast cancers Approximately 25-30 percent of breast cancers, irrespective of whether they are estrogen positive or negative, have an amplification of the Her-2/neu gene or overexpression of its protein product. Overexpression and/or gene amplification of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis.
  • an additional mode of treatment for which prediction is sought is a treatment related to the signalling pathway of a receptor from the ErbB-family, the PDGFR-family and the C-KIT receptor.
  • Such treatment may include the administration of
  • agents may be selected from the group consisting of the agents shown in table 9.
  • Other potential agents may be selected from the group comprising Cetuximab (tradename Erbitux®, target receptor is EGFR), Matuzumab (EMD7200, target receptor is EGFR), Trastuzumab (tradename Herceptin®, target receptor is Her-2/neu), Pertuzumab (target receptor is Her-2/neu), Bevacizumab (tradename Avastin®, target ligand is VEGFA), 2C3 (target ligand is VEGFA), VEGF-trap (AVE-0005, target ligands are VEGFA and PIGF), IMC-1121B (target receptor is VEGFR2), CDP-791 (target receptor is VEGFR2), Gefitinib (tradename Iressa®, ZD-1839, target receptor is EGFR), Erlotinib (tradename Tarceva®, OSI-774, target receptor is EGFR), EKB-569 (target receptor is EGFR), PKI-166 (target receptor is EGFR),), PKI-166
  • parameters may as well be used and combined in order to predict the therapeutic success for said given mode of treatment.
  • the parameters may be chosen from the group consisting of
  • said given mode of treatment (a) acts on recruitment of lymphatic vessels, angiogenesis, cell proliferation, cell survival and/or cell motility, and/or b) comprises administration of a chemotherapeutic agent.
  • said given mode of treatment comprises, in addition, administration of small molecule inhibitors, antibody based regimen, anti-proliferation regimen, pro-apoptotic regimen, pro-differentiation regimen, radiation and/or surgical therapy.
  • the said expression level is determined by a) a hybridization based method
  • said cancer or neoplastic disease is characterized by a negative Estrogen receptor status, a negative progesterone receptor status and/or a negative Her-2/neu receptor status.
  • the group being characterized by negative statuses in all three aspects as mentioned above also termed “basal tumors” has the worst prognosis.
  • a proper detection of this group is thus vital to sort out those patients which will draw any benefit from anti estrogen treatment, anti progestereone treatment and/or anti Her-2/neu treatment.
  • a different type of therapy i.e. neoadjuvant chemotherapy, can thus be administered to these patients, in order to avoid side effects of the above mentioned treatments, and to improve therapy prediction.
  • said cancer or neoplastic disease is selected from the group consisting of gynaecological cancers including Breast cancer, Ovarian cancer, Cervical cancer, Endometrial cancer, Vulval cancer, and the like.
  • the expression level of at least one of the said gene/s is determined with RT-PCR (reverse transcriptase polymerase chain reaction) of the ligand and/or receptor related mRNA.
  • the expression level of at least one of the said gene/s is determined in formalin and/or paraffin fixed tissue samples.
  • the expression level of at least one of the said gene/s is determined in serum, plasma or whole blood samples.
  • RNA samples are taken as biopsies form a patient and undergo diagnostic procedures.
  • the samples are fixed in formalin and/or paraffin and are then examined with immunohistochemistry methods.
  • the formalin treatment leads to the inactivation of enzymes, as for example the ubiquitous RNA-digesting enzymes (RNAses).
  • RNAses ubiquitous RNA-digesting enzymes
  • the mRNA status of the tissue remains unaffected.
  • the samples are treated with silica-coated magnetic particles and a chaotropic salt, in order to purify the nucleic acids contained in said sample for further determination.
  • Collaborators of the inventors of the present invention have developed an approach which however allows successful purification of mRNA out of tissue samples fixed in such manner, and which is disclosed, among others, in WO03058649, WO2006136314A1 and DE10201084A1, the content of which is incorporated herein by reference.
  • Said method comprises the use of magnetic particles coated with silica (SiO 2 ).
  • the silica layer is closed and tight and is characterized by having an extremely small thickness on the scale of a few nanometers.
  • These particles are produced by an improved method that leads to a product having a closed silica layer and thus entail a highly improved purity.
  • the said method prevents an uncontrolled formation of aggregates and clusters of silicates on the magnetite surface whereby positively influencing the additional cited properties and biological applications.
  • the said magnetic particles exhibit an optimized magnetization and suspension behavior as well as a very advantageous run-off behavior from plastic surfaces.
  • These highly pure magnetic particles coated with silicon dioxide are used for isolating nucleic acids, including DNA and RNA, from cell and tissue samples, the separating out from a sample matrix ensuing by means of magnetic fields. These particles are particularly well-suited for the automatic purification of nucleic acids, mostly from biological body samples for the purpose of detecting them with different amplification methods.
  • the said approach is particularly useful for the purification of mRNA out of formalin and/or paraffin fixed tissue samples.
  • the said approach creates mRNA fragments which are large enough to allow specific primer hybridization and/or specific probe hybridization.
  • a minimal size of at least 100 bp, more preferably 200 base pairs is needed for specific and robust detection of target gene expression.
  • Other issues of perturbance of expression data by sample preparation problems relate to the contamination level with DNA, which is lower compared to other bead based technologies. This of particular importance, as the inventors have observed, that DNAse treatment is not efficient in approximately 10% of FFPE samples generated by standard procedures and stored at room temperature for some years before cutting and RNA extraction.
  • the said approach thus allows a highly specific determination of candidate gene expression levels with one of the above introduced methods, particularly with hybridization based methods, PCR based methods and/or array based methods, even in formalin and/or paraffin fixed tissue samples, and is thus extremely beneficial in the context of the present invention, as it allows the use of tissue samples fixed with formalin and paraffin, which are available in tissue banks and connected to clinical databases of sufficient follow-up to allow retrospective analysis.
  • kit useful for carrying out one of the said methods comprising at least
  • a method for correlating the clinical outcome of a patient suffering from or at risk of developing a neoplastic disease comprising the steps of:
  • the said method is particularly beneficial for epidemiological studies. These studies profit from the fact that large tissue databases exist comprising paraffin and/or formalin fixed tissue samples together with an extensive documentation of the patient's history, including etiopathology data, clinical symptoms, anamnesis data and/or data concerning the therapeutic regimen.
  • the said methods allows for large scale studies which comprise the correlation of the clinical outcome of a patient suffering from or at risk of developing a neoplastic disease with a negative or a positive Estrogen receptor status.
  • the above introduced method for mRNA purification comprising silica coated magnetic beads and chaotropic salts is quite helpful.
  • nucleic acid molecule selected from the group consisting of
  • nucleic acids are being used either as primers for a polymerase chain reaction protocol, or as detectable probes for monitoring the said process.
  • the said nucleic acid is selected from the group consisting of DNA, RNA, PNA, LNA and/or Morpholino.
  • the nucleic acid may, in a preferred embodiment, be labelled with at least one detectable marker. This feature is applicable particularly for those nucleic acids which serve as detectable probes for monitoring the polymerase chain reaction process.
  • Such detectable markers may for example comprise at least one label selected from the group consisting of fluorescent molecules, luminescent molecules, radioactive molecules, enzymatic molecules and/or quenching molecules.
  • the said detectable probes are labeled with a fluorescent marker at one end and a quencher of fluorescence at the opposite end of the probe.
  • the close proximity of the reporter to the quencher prevents detection of its fluorescence; breakdown of the probe by the 5′ to 3′ exonuclease activity of the taq polymerase breaks the reporter-quencher proximity and thus allows unquenched emission of fluorescence, which can be detected.
  • An increase in the product targeted by the reporter probe at each PCR cycle therefore causes a proportional increase in fluorescence due to the breakdown of the probe and release of the reporter.
  • kits of primers and/or detection probes comprising at least one of the nucleic acids according to the above enumeration and/or their fractions, variants, homologues, derivatives, fragments, complements, hybridizing counterparts, or molecules sharing a sequence identity of at least 70%, preferably 95%.
  • Said kit may, in another preferred embodiment, comprise at least one of the nucleic acid molecules presented as SEQ ID NO: 1-28, and/or their fractions, variants, homologues, derivatives, fragments, complements, hybridizing counterparts, or molecules sharing a sequence identity of at least 70%, preferably 95%, for the detection of at least one gene of interest.
  • nucleic acid according as recited above, or of a kit as recited above for the prediction of a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards a given mode of treatment.
  • FFPE tissues Core needle biopsy specimen of breast tumors, which had been formalin fixed (FFPE tissues) or were available as fresh tissues were analyzed.
  • Formalin fixed tissues were available from breast cancer patients ( ⁇ cT2, NO/N1, MO) receiving neoadjuvant chemotherapy of 4 cycles of epirubicin and cyclophosphamide (90/600 mg/m2) followed by 4 cycles paclitaxel (175 mg/m 2 ).
  • Trastuzumab was administered parallel to paclitaxel therapy on a three weekly dose (6 mg/kg) and continued for 33 weeks after surgery (according to the TECHNO trial) if tumors were IHC positive (e.g DAKO status 3 with intense and continuous membrane staining) or FISH positive (e.g.
  • Her-2/neu negative tumors patients with Her-2/neu negative tumors (equally to IHCl+ or FISH negative testing) were not treated with trastuzumab (PREPARE trial).
  • the Her-2/neu status was determined in core-needle biopsies of all patients by immunohistochemistry or FISH analysis at a central reference pathology department. In total 853 Paraffin embedded core needle biopsies were used for analysis.
  • 86 fresh tissue specimen were used from breast cancer patients ((cT1-4, N0/N1, MO) receiving neoadjuvant chemotherapy of 4 to 6 cycles of epirubicin and cydophosphamide (90/600 mg/m 2 ) 14 days apart. The samples were flash-frozen and analyzed by microarrays.
  • MMP genes in particular MMP7
  • MLPH MLPH
  • Keratins in particular Keratin 5
  • genes related to the Immune System such as the immunoglobulin gene family (e.g. IGHM, IGHG, IGHD, IGLC, IGLJ, IGLL, IGLV and the like were informative and did predict response to neoadjuvant chemotherapy.
  • immunoglobulin gene family e.g. IGHM, IGHG, IGHD, IGLC, IGLJ, IGLL, IGLV and the like were informative and did predict response to neoadjuvant chemotherapy.
  • the hierarchical clustering based on ESR, PGR, Her-2/neu, and MLPH mRNA expression resulted into 6 identifiable groups, i.e.
  • basal-like subtypes 14 of 217 patients, 6%, group 6 of Example 3 was found to retain some expression of the Her-2/neu, ESR and MLPH genes.
  • VEGF-therapy for example with sunitinib (Sutent), sorafenib (Nexavar), axitinib, and pazopanib.
  • both groups featured a relatively high EGFR gene expression. This means that significantly more patients in the two basal-like subtypes exhibited high EGFR mRNA expression compared to a group of non-basal-like patients (86 of 217, 40%) exhibiting high mRNA expression of all four genes (p ⁇ 0.0001).
  • Survivin is a member of inhibitors of apoptosis (IAPB) family, which are upregulated in various malignancies. It has been described that high survivin expression is associated with favorable outcome of some carcinomas after radiation therapy (Freier et al. (2007).
  • group 3 tumors while not likely to be affected by anti VEGF therapy, might be susceptible to radiation therapy.
  • FIG. 1 A first figure.
  • the inventors have further analyzed said genes in breast carcinomas treated with neoadjuvant chemotherapeutic treatments (e.g. EC, EC-T, TAC) to analyze whether these tumors do respond to chemotherapeutic regimen.
  • neoadjuvant chemotherapeutic treatments e.g. EC, EC-T, TAC
  • HG U133A Affymetrix array analysis
  • RT-kPCR analysis in fixed tissue biopsies of high risk breast tumors. It was found that >60% of these tumors do respond to chemotherapeutic regimen by pathological complete response, meaning no tumor is left after chemotherapeutic regimen in the primary tumor site or in the lymphnodes.
  • tumors were further selected on basis of high immune marker expression, such as IGHM expression levels, approximately 90% of the tumors having high MMP7 and low MLPH level exhibited pathological complete response as depicted in FIG. 2 .
  • Her-2/neu over-expression are important prognostic variables in patients with operable breast cancer.
  • the majority of basal-like tumors are triple-negative for estrogen receptors (ESR), progesterone (PGR) and Her-2/neu receptors.
  • ESR estrogen receptors
  • PGR progesterone
  • Her-2/neu receptors Such tumors are found in approximately 120 of breast cancer patients and have been shown to have a poor prognosis.
  • FIG. 2 shows identification of the basal-like subtypes based on 2D hierarchical clustering, as described in Example 3. Green indicates low gene expression, whereas red indicates high gene expression The Molecular classification was based on only four genes (estrogen receptors (ESR), progesterone receptors (PGR), Her-2/neu, and melanophilin (MLPH).
  • ESR estrogen receptors
  • PGR progesterone receptors
  • MLPH melanophilin
  • Tumor groups classifiable with the method according to the invention, and possible therapies Marker status/ Group expression level Tumor status Therapy approach 1 ESR and PGR ESR positive Endocrine therapy, positive i.e. tamoxifen 5 ESR and Her-2/neu ESR positive Endocrine therapy positive, PGR on a in combination with medium level anti-ErbB therapy (i.e. trastuzumab) 4 ESR on a medium level, PGR negative, Her-2/neu 6 some residual ESR “triple negative”, anti VEGF therapy and Her-2/neu activity Basal like Tumor (i.e. Nexavar); left, PGR negative optionally: new anti-ErbB therapy 2 Her-2/neu positive anti ErbB therapy and ESR negative (i.e.
  • trastuzumab 3 ESR and PGR almost “triple negative”, anti VEGF therapy zero, some residual Basal like Tumor (i.e. Nexavar); Her-2/neu activity left Birc5 (survivin) optionally: new high anti-ErbB therapy. Radiotherapy due to coexpression of Birc5
  • groups 3 and 6 can be further specified with respect to their CCND, BRCA1 and RB1 status, namely by means of detecting the MMP7 and/or MLPH status. This in turn may open up complementary therapeutic approaches:
  • Tumor groups classifiable with another method according to the invention, and possible therapies Marker status/ Group expression level Tumor status Therapy approach 3 or 6 MMP7 positive CCND negative inhibition of and/or RB1 negative homologous MLPH positive BRCA1 negative recombination repair (e.g. PARP1 inhibition)
  • FIGS. 3 and 4 show Kaplan Meyer curves in which, for the different groups determined as above (see Example 3), the overall survival time (OAS) is plotted versus the respective percentage. It is obvious that the basal-like subtypes (groups 6 and 3) have the worst survival rates, and are thus associated with poor prognosis. For this reason, it is vital that the method according to the invention provides a method to detect these subtypes, in order to submit the respective patients to different and/or novel treatments.
  • OFAS overall survival time

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of:
    • a) obtaining a biological sample from said patient;
    • b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample,
    • c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and
    • d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c).

Description

    CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 12/745,668, filed Dec. 21, 2010, which is a U.S. national phase application of International Application No. PCT/EP2008/065040, which was filed Nov. 6, 2008, and which claims the benefit of priority to U.S. Provisional Application No. 60/991,391, filed on Nov. 30, 2007. The content of these earlier filed applications is hereby incorporated herein by reference.
    • SEQUENCE LISTING
  • The Sequence Listing submitted herewith as a text filed named “13318_0032U3_Sequence_Listing.txt,” created on Mar. 2, 2018, and having a size of 8,192 bytes is hereby incorporated by reference pursuant to 37 C.F.R. § 1.52(e) (5).
    • FIELD OF THE INVENTION
  • The present invention relates to methods for prediction of the therapeutic success of cancer therapy.
    • BACKGROUND OF THE INVENTION
  • In some neoplastic diseases, particularly gynaecological cancers like breast cancer, the response to neoadjuvant chemotherapy is comparatively low, with only about 20% of patients achieving pathological complete remission (pCR) with no tumor cells left in the breast or lymph nodes; the latter being the strongest prognostic factor for prolonged survival due to treatment benefit to date.
  • However, a substantial number of patients suffer severe side effects (ADRs) from highly toxic drug combinations (e.g. alopecia due to inclusion of taxanes) without additional benefit. In addition, there is a burden on national health systems due to the high cost of some therapies in this regime, especially if the chemotoxic treatments are combined with new tareted treatment options (e.g. Herceptin®, Lapatinib® and Avastin®). Moreover the new treatment options are related with some severe, probably life threatening side effects (e.g. cardiac toxicities upon combinatorial treatment with Herceptin®, gastrointestinal perforation upon combinatorial treatment with Avastin).
  • A better characterization of the respective tumors would thus allow a better selection of the most promising therapy in a given breast cancer patient, in order to avoid unnecessary side effects due to neoadjuvant chemotherapy in those patients which do no not draw any benefit from such therapy anyway.
  • Some neoplastic diseases, particularly gynaecological cancers like breast cancer (BC), are characterized the fact that approximately 80% of them are estrogen receptor positive as characterized by standard immunohistochemistry, i.e. the exhibit estrogen receptors. However, it turned out that only a fraction of these tumors are dependent on hormone ligands (i.e. estrogen) for activation of Estrogen receptors (ESR) and sustained growth of the tumor tissue.
  • The estrogen receptor is a member of the nuclear hormone family of intracellular receptors which is activated by the hormone 17-β-estradiol (estrogen). The main function of the estrogen receptor is that of a DNA binding transcription factor which regulates gene expression. In addition a subfraction of estrogen receptor is able to interact with receptor tyrosine kinases (e.g. Her-2/neu) on the membrane which is critical for development of resistance towards cancer therapeutics.
  • Estrogen and the ESRs have also been implicated in breast cancer, ovarian cancer, colon cancer, prostate cancer and endometrial cancer. Advanced colon cancer is associated with a loss of ERβ (also termed ESR2), the predominant ESR in colon tissue, and colon cancer is treated with ERβ specific agonists in some cases.
  • As stated above, Estrogen receptors are overexpressed on the protein level in around 80% of breast cancer cases, referred to as “ESR positive”. Two hypotheses have been proposed to explain why this causes tumorigenesis. One stipulates that binding of estrogen to the ESR stimulates proliferation of mammary cells, with the resulting increase in cell division and DNA replication leading to mutations. The other one states that estrogen metabolism produces genotoxic waste.
  • The result of both processes is disruption of cell cycle, apoptosis and DNA repair and therefore tumor formation or growth.
  • Different versions of the ESR1 (also termed ERα), gene have been identified (with single-nucleotide polymorphisms) and are associated with different risks of developing breast cancer.
  • It has turned out that, typically, ESR-positive tumors demonstrate only poor responses on neoadjuvant chemotherapy, with about 10% pathological complete remission (pCR) reported.
  • However, ESR-positive tumors may profit from a treatment with Tamoxifen, an estrogen-receptor antagonist used as an adjuvant hormonal treatment. Another selective estrogen receptor modulator, raloxifene, has been used as a preventative chemotherapy for women judged to have a high risk of developing breast cancer. Another anti-estrogen, ICI 182,780 (Faslodex) which acts as a complete antagonist also promotes degradation of the estrogen receptor.
  • Other anti estrogen drugs are Anastrozole (Arimidex®), a drug which prevents the conversion of adrenal gland androgen hormones to estrogen, Exemestane (Aromasin®) and Letrozole (Ferrara®), which are inhibitors for the enzyme aromatase which is involved in the production of estrogen, and Megestrol acetate (Megace®) which is a progesteron agonist acting through competitive inhibition.
  • One current standard for diagnosis of early breast cancer is the determination of ESR1 by immunohistochemistry (IHC) using subsequent scoring systems. These assays are based on Protein-level measurements exhibiting limited quantitative performance and comparatively high inter- and intra-assay variabilities. Moreover, the final assessment is essentially subjective and is known to show substantial inter-operator (i.e. inter-pathologist) variance (Faneyte et al., 2003).
  • In this context, it has been shown that as few as 1 to 5% of ESR1 positive tumor cells within a given tumor are sufficient to specify this tumor as being potentially responsive to endocrine treatment. This is somewhat surprising as one would rather think that the 95% to 99% ESR1 protein negative tumor cells should not be dependent on estrogen and thereby not be responsive to endocrine treatment as described above. Conversely, this already shows the limitations of the protein determination of estrogen receptors as being insufficient to describe estrogen receptor dependent tumors. Clinically the 95% to 99% of estrogen receptor negative tumor cells have a high potential to be hormone dependent. Moreover, the determination of estrogen receptor status based on immunohistochemistry is highly subjective and varies between different labs (approximately 70% concordance). In view, of the marginal protein expression level of estrogen receptor being necessary to qualify for endocrine treatment this is critical.
  • Moreover, there are apparent differences between ESR1 positive tumors, which clearly separate the growth characteristics and dependency on solely estrogen. For example, it has been shown that a significant fraction of estrogen receptor coexpress progesteron receptor and/or the receptor tyrosine kinase Her-2/neu. This raises e.g. the possibility of estrogen independent growth capabilities via progesterone or EGFR family ligands.
  • Nevertheless, Estrogen receptor positive tumors do have a comparably good prognosis, while Estrogen receptor negative tumors as determined by IHC have a particularly bad prognosis.
  • It has yet been reported that about 20% of breast cancer cases are independent of estrogen, and are thus resistant against anti estrogen treatments (Ring et al., 2004).
  • These tumors, however, seem to demonstrate a better response towards chemotherapy, with about 20% pathological complete remission (pCR) reported. In addition, if Her-2/neu positive, these tumors may additionally have benefit from anti-Her-2/neu regimen such as Herceptin™ or Tykerb™. Apparently, bad prognosis tumors particularly bear the potential of benefit from combined antibody and chemotherapeutic regimen.
  • Still, not at least in view of the new therapeutic options, the worst prognosis among the breast cancer subgroups do have estrogen receptor negative, progesterone receptor negative and Her-2/neu receptor negative breast cancer, which are also the so called “basal like tumors” as originally defined by multiparametric gene array analysis by unsupervised cluster analysis (Sorlie et al., 2001)
  • However, the precise definition of the so called “basal like tumors” has been defined by fresh tissue RNA analysis using multigene arrays, and the definition of the “basal like tumors” by immunohistochemistry in fixed tissue routine samples is far from being adaequate. Moreover, the “basal like tumors” itself seem to be clinically heterogenous and do contain two very different subtypes, one of which seems to have a particularly good response to chemotherapy.
  • A proper differentiation between these two “basal like” tumor subclasses would help to apply or develop patient or tumor specific therapies, in order to reduce side effects and improve tumor remission rates.
  • Moreover, new targets for newly available targeted drugs, or drugs yet to be developed, could thus be determined.
  • It is obvious that current methods do not suffice to characterize a high risk or low risk “basal like tumor” in a reliable and reproducible way by immunohistochemically determining it as ESR-negative, PR-negative and Her-2/neu negative.
    • Definitions
  • The term “determining the expression level of a gene/protein on a non protein basis” relates to methods which are not restricted to the secondary gene translation products, i.e proteins, but on other levels of the gene expression, like the mRNA, premRNA and genomic DNA structures.
  • The terms “positive receptor status” and “negative receptor status” relate to the presence or absence of a given receptor, e.g. ESR, PGR or Her-2/neu, in a tissue sample. Usually, the respective status is being determined by IHC.
  • The term “chemotherapy” relates to a drug therapy which affects cell growth and cell division, i.e. which acts as a cytostatic, or which induces cell death (apoptosis). Due to their uncontrolled growth and division, cancer cells are supposed to be more affected by chemotherapy than normal cells.
  • The term “neoadjuvant therapy” relates to a preoperative therapy regimen consisting of a panel of hormonal, chemotherapeutic and/or antibody agents, which is aimed to shrink the primary tumour, thereby rendering local therapy (surgery or radiotherapy) less destructive or more effective, enabling breast conserving surgery and evaluation of responsiveness of tumor sensitivity towards specific agents in vivo.
  • The term “targeted therapy” refers to a therapy which aims at recognizing particular target molecules, which may play a role in tumor genesis or proliferation, or cell repair, for example. Such recognition may for example lead to a binding of the said target molecule, which may either enhance or decrease its activity. Drugs used for such therapy comprise, among others, antibodies, particularly monoclonal antibodies, and small molecular drugs.
  • Potential targets are, for example, the EGFR receptor (which plays an important role in angiogenesis), the VEGFA ligand (likewise important for angiogenesis) or PARP1 (important for cell repair, as its inhibition makes tumors characterized by oncogene defects more susceptive to chemotherapy).
  • The term “prediction”, as used herein, relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (DFS, disease free survival; OAS, overall survival; DSS, Disease specific survival) of a patient, if the tumor is treated with a given therapy. In contrast thereto, the term “prognosis” relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (DFS, disease free survival; OAS, overall survival; DSS, Disease specific survival) of a patient, unaffected and/or independent of the tumor treatment.
  • The term “response marker” relates to a marker which can be used to predict the clinical response and/or clinical outcome of a patient towards a given treatment.
  • The term “neoplastic lesion” or “neoplastic disease” or “neoplasia” refers to a cancerous tissue this includes carcinomas, (e.g., carcinoma in situ, invasive carcinoma, metastatic carcinoma) and pre-malignant conditions, neomorphic changes independent of their histological origin (e.g. ductal, lobular, medullary, mixed origin). The term “cancer” as used herein includes carcinomas, (e.g., carcinoma in situ, invasive carcinoma, metastatic carcinoma) and pre-malignant conditions, neomorphic changes independent of their histological origin. The term “cancer” is not limited to any stage, grade, histomorphological feature, invasiveness, agressivity or malignancy of an affected tissue or cell aggregation. In particular stage 0 cancer, stage I cancer, stage II cancer, stage III cancer, stage IV cancer, grade I cancer, grade II cancer, grade III cancer, malignant cancer, primary carcinomas, and all other types of cancers, malignancies and transformations associated with the lung, ovar, cervix, endometrium, esophagus, stomach, pancreas, prostate, head and neck, renal cell, liver, colorectal or breast cancer are included. Particularly types of adenocarcinoma are included, as well as all carcinomas of unknown primary (cup-syndromes).
  • The terms “neoplastic lesion” or “neoplastic disease” or “neoplasia” or “cancer” are not limited to any tissue or cell type they also include primary, secondary or metastatic lesions of cancer patients, and also comprises lymph nodes affected by cancer cells or minimal residual disease cells either locally deposited (e.g. bone marrow, liver, kidney) or freely floating throughout the patient's body.
  • The term “neoplastic cells” refer to abnormal cells that grow by cellular proliferation more rapidly than normal. As such, neoplastic cells of the invention may be cells of a benign neoplasm or may be cells of a malignant neoplasm.
  • Furthermore, the term “characterizing the state of a neoplastic disease” is related to, but not limited to, measurements and assessment of one or more of the following conditions: Type of tumor, histomorphological appearance, dependence on external signal (e.g. hormones, growth factors), invasiveness, motility, state by TNM (2) or similar, agressivity, malignancy, metastatic potential, and responsiveness to a given therapy.
  • The term “Her-2/neu” relates to a gene encoding for a cell signalling protein. Synonyms for this gene are “ErbB” or “ERBB”. The three terms are being used interchangeably in this specification.
  • The terms “biological sample” or “clinical sample”, as used herein, refer to a sample obtained from a patient. The sample may be of any biological tissue or fluid. Such samples include, but are not limited to, sputum, blood, serum, plasma, blood cells (e.g., white cells), circulating cells (e.g. stem cells or endothelial cells in the blood, tissue, core or fine needle biopsy samples, cell-containing body fluids, free floating nucleic acids, urine, stool, peritoneal fluid, and pleural fluid, liquor cerebrospinalis, tear fluid, or cells there from. Biological samples may also include sections of tissues such as frozen or fixed sections taken for histological purposes or microdissected cells or extracellular parts thereof. A biological sample to be analyzed is tissue material from a neoplastic lesion taken by aspiration or punctuation, excision or by any other surgical method leading to biopsy or resected cellular material. Such a biological sample may comprise cells obtained from a patient. The cells may be found in a cell “smear” collected, for example, by a nipple aspiration, ductal lavarge, fine needle biopsy or from provoked or spontaneous nipple discharge. In another embodiment, the sample is a body fluid. Such fluids include, for example, blood fluids, serum, plasma, lymph, ascitic fluids, gynecological fluids, or urine but not limited to these fluids.
  • The term “therapy modality”, “therapy mode”, “regimen” or “chemo regimen” as well as “therapy regimen” refers to a timely sequential or simultaneous administration of anti-tumor, and/or anti vascular, and/or anti stroma, and/or immune stimulating, and/or blood cell proliferative agents, and/or radiation therapy, and/or hyperthermia, and/or hypothermia for cancer therapy. The administration of these can be performed in an adjuvant and/or neoadjuvant mode. The composition of such “protocol” may vary in the dose of each of the single agents, timeframe of application and frequency of administration within a defined therapy window. Currently various combinations of various drugs and/or physical methods, and various schedules are under investigation.
  • By “array” or “matrix” an arrangement of addressable locations or “addresses” on a device is meant. The locations can be arranged in two dimensional arrays, three dimensional arrays, or other matrix formats. The number of locations can range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site. Arrays include but are not limited to nucleic acid arrays, protein arrays and antibody arrays. A “nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides, nucleotide analogues, polynucleotides, polymers of nucleotide analogues, morpholinos or larger portions of genes. The nucleic acid and/or analogue on the array is preferably single stranded. Arrays wherein the probes are oligonucleotides are referred to as “oligonucleotide arrays” or “oligonucleotide chips.” A “microarray,” herein also refers to a “biochip” or “biological chip”, an array of regions having a density of discrete regions of at least about 100/cm2, and preferably at least about 1000/cm2. The regions in a microarray have typical dimensions, e.g., diameters, in the range of between about 10-250 μm, and are separated from other regions in the array by about the same distance. A “protein array” refers to an array containing polypeptide probes or protein probes which can be in native form or denatured. An “antibody array” refers to an array containing antibodies which include but are not limited to monoclonal antibodies (e.g. from a mouse), chimeric antibodies, humanized antibodies or phage antibodies and single chain antibodies as well as fragments from antibodies.
  • The term “small molecule”, as used herein, is meant to refer to a compound which has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic (carbon-containing) or inorganic molecules. Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention to identify compounds that modulate a bioactivity.
  • The terms “modulated” or “modulation” or “regulated” or “regulation” and “differentially regulated” as used herein refer to both upregulation [i.e., activation or stimulation, e.g., by agonizing or potentiating] and down regulation [i.e., inhibition or suppression, e.g., by antagonizing, decreasing or inhibiting].
  • The term “transcriptome” relates to the set of all messenger RNA (mRNA) molecules, or “transcripts”, produced in one or a population of cells. Importantly, this term includes also non-translated RNAs such as “micro RNA's”, which affect cellular characteristics because of gene regulation functions (silencing or activation or stabilization or degradation of other genes and transcripts). The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. Unlike the genome, which is roughly fixed for a given cell line (excluding mutations), the transcriptome can vary with external environmental conditions. Because it includes all RNA transcripts in the cell, the transcriptome reflects the genes that are being actively expressed at any given time, with the exception of mRNA degradation phenomena such as transcriptional attenuation. It also includes posttranscriptional events such as alternative splicing. The discipline of transcriptomics examines the expression level of mRNAs in a given cell population, often using high-throughput techniques based on DNA microarray technology.
  • The term “expression levels” refers, e.g., to a determined level of gene expression. The term “pattern of expression levels” refers to a determined level of gene expression compared either to a reference gene (e.g. housekeeper or inversely regulated genes) or to a computed average expression value (e.g. in DNA-chip analyses). A pattern is not limited to the comparison of two genes but is more related to multiple comparisons of genes to reference genes or samples. A certain “pattern of expression levels” may also result and be determined by comparison and measurement of several genes disclosed hereafter and display the relative abundance of these transcripts to each other.
  • Alternatively, a differentially expressed gene disclosed herein may be used in methods for identifying reagents and compounds and uses of these reagents and compounds for the treatment of cancer as well as methods of treatment. The differential regulation of the gene is not limited to a specific cancer cell type or clone, but rather displays the interplay of cancer cells, muscle cells, stromal cells, connective tissue cells, other epithelial cells, endothelial cells of blood vessels as well as cells of the immune system (e.g. lymphocytes, macrophages, killer cells).
  • A “reference pattern of expression levels”, within the meaning of the invention shall be understood as being any pattern of expression levels that can be used for the comparison to another pattern of expression levels. In a preferred embodiment of the invention, a reference pattern of expression levels is, e.g., an average pattern of expression levels observed in a group of healthy or diseased individuals, serving as a reference group.
  • “Primer pairs” and “probes”, within the meaning of the invention, shall have the ordinary meaning of this term which is well known to the person skilled in the art of molecular biology. In a preferred embodiment of the invention “primer pairs” and “probes”, shall be understood as being polynucleotide molecules having a sequence identical, complementary, homologous, or homologous to the complement of regions of a target polynucleotide which is to be detected or quantified. In yet another embodiment nucleotide analogues and/or morpholinos are also comprised for usage as primers and/or probes.
  • “Individually labeled probes”, within the meaning of the invention, shall be understood as being molecular probes comprising a polynucleotide, oligonucleotide or nucleotide analogue and a label, helpful in the detection or quantification of the probe. Preferred labels are fluorescent molecules, luminescent molecules, radioactive molecules, enzymatic molecules and/or quenching molecules.
  • “Arrayed probes”, within the meaning of the invention, shall be understood as being a collection of immobilized probes, preferably in an orderly arrangement. In a preferred embodiment of the invention, the individual “arrayed probes” can be identified by their respective position on the solid support, e.g., on a “chip”.
  • The phrase “tumor response”, “therapeutic success”, or “response to therapy” refers, in the adjuvant chemotherapeutic setting to the observation of a defined tumor free or recurrence free survival time (e.g. 2 years, 4 years, 5 years, 10 years). This time period of disease free survival may vary among the different tumor entities but is sufficiently longer than the average time period in which most of the recurrences appear. In a neo-adjuvant therapy modality, response may be monitored by measurement of tumor shrinkage and regression due to apoptosis and necrosis of the tumor mass.
  • The term “recurrence” or “recurrent disease” includes distant metastasis that can appear even many years after the initial diagnosis and therapy of a tumor, or local events such as infiltration of tumor cells into regional lymph nodes, or occurrence of tumor cells at the same site and organ of origin within an appropriate time.
  • “Prediction of recurrence” or “prediction of therapeutic success” does refer to the methods described in this invention. Wherein a tumor specimen is analyzed for it's gene expression and furthermore classified based on correlation of the expression pattern to known ones from reference samples. This classification may either result in the statement that such given tumor will develop recurrence and therefore is considered as a “non responding” tumor to the given therapy, or may result in a classification as a tumor with a prolonged disease free post therapy time.
  • “Biological activity” or “bioactivity” or “activity” or “biological function”, which are used interchangeably, herein mean an effector or antigenic function that is directly or indirectly exerted by a polypeptide (whether in its native or denatured conformation), or by any fragment thereof in vivo or in vitro. Biological activities include but are not limited to binding to polypeptides, binding to other proteins or molecules, enzymatic activity, signal transduction, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc. A bioactivity can be modulated by directly affecting the subject polypeptide. Alternatively, a bioactivity can be altered by modulating the level of the polypeptide, such as by modulating expression of the corresponding gene.
  • The term “marker” or “biomarker” refers to a biological molecule, e.g., a nucleic acid, peptide, protein, hormone, etc., whose presence or concentration can be detected and correlated with a known condition, such as a disease state.
  • The term “ligand”, as used herein, relates to a molecule that is able to bind to and form a complex with a biomolecule to serve a biological purpose. In a narrower sense, it is an effector molecule binding to a site on a target protein, by intermolecular forces such as ionic bonds, hydrogen bonds and Van der Waals forces. The docking (association) is usually reversible (dissociation). Actual irreversible covalent binding between a ligand and its target molecule is rare in biological systems. Ligand binding to receptors often alters the chemical conformation, i.e. the three dimensional shape of the receptor protein. The conformational state of a receptor protein determines the functional state of a receptor. The tendency or strength of binding is called affinity. Ligands include substrates, inhibitors, activators, and neurotransmitters.
  • The term “agonist”, as used herein, relates to a substance that binds to a specific receptor and triggers a response in the cell. It mimics the action of an endogenous ligand that binds to the same receptor.
  • The term “receptor”, as used herein, relates to a protein on the cell membrane or within the cytoplasm or cell nucleus that binds to a specific molecule (a ligand), such as a neurotransmitter, hormone, or other substance, and initiates the cellular response to the ligand. Ligand-induced changes in the behavior of receptor proteins result in physiological changes that constitute the biological actions of the ligands.
  • The term “signalling pathway” is related to any intra- or intercellular process by which cells converts one kind of signal or stimulus into another, most often involving ordered sequences of biochemical reactions out- and inside the cell, that are carried out by enzymes and linked through hormones and growth factors (intercellular), as well as second messengers (intracellular), the latter resulting in what is thought of as a “second messenger pathway”. In many signalling pathways, the number of proteins and other molecules participating in these events increases as the process emanates from the initial stimulus, resulting in a “signal cascade” and often results in a relatively small stimulus eliciting a large response.
  • The term “marker gene,” as used herein, refers to a differentially expressed gene whose expression pattern may be utilized as part of a predictive, prognostic or diagnostic process in healthy conditions, premalignant disease status, malignant neoplasia or cancer evaluation, or which, alternatively, may be used in methods for identifying compounds useful for the treatment or prevention of malignant neoplasia and head and neck, colon or breast cancer in particular. A marker gene may also have the characteristics of a target gene.
  • “Target gene”, as used herein, refers to a differentially expressed gene involved in cancer or pre-cancerous lesions, e.g., lung, head and neck, colon, ovarian or breast cancer in a manner in which modulation of the level of the target gene expression or of the target gene product activity may act to ameliorate symptoms of malignant neoplasia and lung, liver, endometrium, ovarian, cervix, esophagus, stomach, pancreas, prostate, head and neck, renal cell, colorectal or breast cancer in particular. A target gene may also have the characteristics of a marker gene.
  • The term “expression level”, as used herein, relates to each step within the process by which a gene's DNA sequence is converted into functional protein (i.e. ligands) via RNA intermediates and particularly to the amount of said conversion.
  • The term “hybridization based method”, as used herein, refers to methods imparting a process of combining complementary, single-stranded nucleic acids or nucleotide analogues into a single double stranded molecule. Nucleotides or nucleotide analogues will bind to their complement under normal conditions, so two perfectly complementary strands will bind to each other readily. In bioanalytics, very often labeled, single stranded probes are in order to find complementary target sequences. If such sequences exist in the sample, the probes will hybridize to said sequences which can then be detected due to the label. Other hybridization based methods comprise microarray and/or biochip methods. Therein, probes are immobilized on a solid phase, which is then exposed to a sample. If complementary nucleic acids exist in the sample, these will hybridize to the probes and can thus be detected. These approaches are also known as “array based methods”. Yet another hybridization based method is PCR, which is described below. When it comes to the determination of expression levels, hybridization based methods may for example be used to determine the amount of mRNA for a given gene.
  • “Serial analysis of gene expression” (SAGE) is a method for comprehensive analysis of gene expression patterns, which is based on the facts that (i) a short sequence tag (10-14 bp) contains sufficient information to uniquely identify a transcript provided that that the tag is obtained from a unique position within each transcript; (ii) sequence tags can be linked together to from long serial molecules that can be cloned and sequenced; and (iii) quantitation of the number of times a particular tag is observed provides the expression.
  • The term “a PCR based method” as used herein refers to methods comprising a polymerase chain reaction (PCR). This is a method of exponentially amplifying nucleic acids, e.g. DNA by enzymatic replication in vitro. As PCR is an in vitro technique, it can be performed without restrictions on the form of DNA, and it can be extensively modified to perform a wide array of genetic manipulations. When it comes to the determination of expression levels, a PCR based method may for example be used to detect the presence of a given mRNA by (1) reverse transcription of the complete mRNA pool (the so called transcriptome) into cDNA with help of a reverse transcriptase enzyme, and (2) detecting the presence of a given cDNA with help of respective primers. This approach is commonly known as reverse transcriptase PCR (rtPCR).
  • Moreover, PCR-based methods comprise e.g. real time PCR, and, particularly suited for the analysis of expression levels, kinetic or quantitative PCR (qPCR).
  • The term “Quantitative real-time PCR” (qPCR)” refers to any type of a PCR method which allows the quantification of the template in a sample. Quantitative real-time PCR comprise different techniques of performance or product detection as for example the TaqMan technique or the LightCycler technique. The TaqMan technique, for examples, uses a dual-labelled fluorogenic probe. The TaqMan real-time PCR measures accumulation of a product via the fluorophore during the exponential stages of the PCR, rather than at the end point as in conventional PCR. The exponential increase of the product is used to determine the threshold cycle, CT, i.e. the number of PCR cycles at which a significant exponential increase in fluorescence is detected, and which is directly correlated with the number of copies of DNA template present in the reaction. The set up of the reaction is very similar to a conventional PCR, but is carried out in a real-time thermal cycler that allows measurement of fluorescent molecules in the PCR tubes. Different from regular PCR, in TaqMan real-time PCR a probe is added to the reaction, i.e., a single-stranded oligonucleotide complementary to a segment of 20-60 nucleotides within the DNA template and located between the two primers. A fluorescent reporter or fluorophore (e.g., 6-carboxyfluorescein, acronym: FAM, or tetrachlorofluorescin, acronym: TET) and quencher (e.g., tetramethylrhodamine, acronym: TAMRA, of dihydrocyclopyrroloindole tripeptide “minor groove binder”, acronym: MGB) are covalently attached to the 5′ and 3′ ends of the probe, respectively[2]. The close proximity between fluorophore and quencher attached to the probe inhibits fluorescence from the fluorophore. During PCR, as DNA synthesis commences, the 5′ to 3′ exonuclease activity of the Taq polymerase degrades that proportion of the probe that has annealed to the template (Hence its name: Taq polymerase+PacMan). Degradation of the probe releases the fluorophore from it and breaks the close proximity to the quencher, thus relieving the quenching effect and allowing fluorescence of the fluorophore. Hence, fluorescence detected in the real-time PCR thermal cycler is directly proportional to the fluorophore released and the amount of DNA template present in the PCR.
  • The term “planar waveguide” (PWG) relates to detection chips and chambers for performing multiplex PCR assays, as for example disclosed in WO2007059423, which has been filed by the applicant of the present invention and which is incorporated herein by reference. Such planar waveguides may be used in methods of performing a multiplex polymerase chain reaction (PCR) assay with a single fluorogenic dye. Compared to other biochips or microarrays they have a far better sensitivity and do thus put aside the need of an additional amplification step.
  • The term “determining the protein level”, as used herein, refers to methods which allow the quantitative and/or qualitative determination of one or more proteins in a sample. These methods include, among others, protein purification, including ultracentrifugation, precipitation and chromatography, as well as protein analysis and determination, including the use protein microarrays, two-hybrid screening, blotting methods including western blot, one- and two dimensional gel electrophoresis, isoelectric focusing as well as methods being based mass spectrometry like MALDI-TOF and the like.
  • The term “method based on the electrochemical detection of molecules” relates to methods which make use of an electrode system to which molecules, particularly biomolecules like proteins, nucleic acids, antigens, antibodies and the like, bind under creation of a detectable signal. Such methods are for example disclosed in WO0242759, WO0241992 and WO02097413 filed by the applicant of the present invention, the content of which is incorporated by reference herein. These detectors comprise a substrate with a planar surface which is formed, for example, by the crystallographic surface of a silicon chip, and electrical detectors which may adopt, for example, the shape of interdigital electrodes or a two dimensional electrode array. These electrodes carry probe molecules, e.g. nucleic acid probes, capable of binding specifically to target molecules, e.g. target nucleic acid molecules. The probe molecules are for example immobilized by a Thiol-Gold-binding. For this purpose, the probe is modified at its 5′- or 3′-end with a thiol group which binds to the electrode comprising a gold surface. These target nucleic acid molecules may carry, for example, an enzyme label, like horseradish peroxidise (HRP) or alkaline phosphatase. After the target molecules have bound to the probes, a substrate is then added (e.g., α-naphthyl phosphate or 3,3′5,5′-tetramethylbenzidine which is converted by said enzyme, particularly in a redox-reaction. The product of said reaction, or a current generated in said reaction due to an exchange of electrons, can then be detected with help of the electrical detector in a site specific manner.
  • The term “anamnesis” relates to patient data gained by a physician or other healthcare professional by asking specific questions, either of the patient or of other people who know the person and can give suitable information (in this case, it is sometimes called heteroanamnesis), with the aim of obtaining information useful in formulating a diagnosis and providing medical care to the patient. This kind of information is called the symptoms, in contrast with clinical signs, which are ascertained by direct examination.
  • The term “etiopathology” relates to the course of a disease, that is its duration, its clinical symptoms, and its outcome.
  • The term “detection of a ligand and/or receptor” as used herein means both the qualitative detection of the presence of the respective gene as well as the quantitative detect detection of the expression level of the respective gene, e.g. by quantitative reverse transcriptase PCR.
  • The term “nucleic acid molecule” is intended to indicate any single- or double stranded nucleic acid molecule comprising DNA (cDNA and/or genomic DNA), RNA (preferably mRNA), PNA, LNA and/or Morpholino.
  • The term “stringent conditions” relates to conditions under which a probe will preferably hybridize to its target subsequence and much less to other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at Tm, 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g. 10 to 50 nucleotides) and at least about 60° C. for longer probes. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide and the like.
  • The term “fragment of the nucleic acid molecule” is intended to indicate a nucleic acid comprising a subset of a nucleic acid molecule according to one of the claimed sequences. The same is applicable to the term “fraction of the nucleic acid molecule”.
  • The term “variant of the nucleic acid molecule” refers herein to a nucleic acid molecule which is substantially similar in structure and biological activity to a nucleic acid molecule according to one of the claimed sequences.
  • The term “homologue of the nucleic acid molecule” refers to a nucleic acid molecule the sequence of which has one or more nucleotides added, deleted, substituted or otherwise chemically modified in comparison to a nucleic acid molecule according to one of the claimed sequences, provided always that the homologue retains substantially the same binding properties as the latter.
  • The term “derivative”, as used herein, refers to a nucleic acid molecule that has similar binding characteristics to a target nucleic acid sequence as a nucleic acid molecule according to one of the claimed sequences.
  • The term “sequence identity of at least X %” refers to a sequence identity as determined after a sequence alignment carried out with the family of BLAST algorithms as accessible on the respective Internet domain provided by NCBI.
    • OBJECT OF THE INVENTION
  • It is one object of the present invention to detect cancer subtypes which are characterized in that they are estrogen receptor negative, progesterone receptor negative and Her-2/neu receptor negative (“basal type tumors”), in order to provide chemotherapeutic and/or antibody based regimen specially suitable for these cancer types.
  • It is another object of the present invention to provide means to further differentiate between different basal type tumor subgroups.
  • It is another object of the present invention to identify basal type tumors having high probability to respond to chemotherapy regimen (“low risk basal type tumors”), and/or to identify basal type tumors that do not respond to chemotherapy (“high risk basal type tumors”) in order to identify target genes that might serve as more effective treatment alternatives.
  • It is another object of the present invention to offer a more robust and specific diagnostic assay system than conventional immunohistochemistry for clinical routine fixed tissue samples that better helps the physician to select individualized treatment modalities. In a more preferred embodiment the disclosed method can be used to select chemotherapeutic and/or antibody based regimen for breast cancers exhibiting reduced estrogen receptor expression on RNA and or/protein level.
  • It is another object of the present invention to detect new targets for newly available targeted drugs, or to determine drugs yet to be developed.
    • SUMMARY OF THE INVENTION
  • Before the invention is described in detail, it is to be understood that this invention is not limited to the particular component parts of the devices described or process steps of the methods described as such devices and methods may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include singular and/or plural referents unless the context clearly dictates otherwise. It is moreover to be understood that, in case parameter ranges are given which are delimited by numeric values, the ranges are deemed to include these limitation values.
  • According to the invention, a method is provided for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of:
      • a) obtaining a biological sample from said patient;
      • b) determining, on a non-protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample,
      • c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and
      • d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c).
    BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows results of an Affymetrix array analysis (HG U133A) in fresh tissue biopsies or RT-kPCR analysis in fixed tissue biopsies of high risk breast tumors.
  • FIG. 2 shows identification of the basa-like subtypes based on 2D hierarchial clustering.
  • FIG. 3 shows a Kaplan Meyer curve in which, for the different groups determined as above (see Example 3, the overall survival time (OAS) is plotted versus the respective percentage.
  • FIG. 4 shows a Kaplan Meyer curve in which, for the different groups determined as above (see Example 3, the overall survival time (OAS) is plotted versus the respective percentage.
    •
  • Basically, a deviating expression level of either of the aformentioned genes can have different reasons, these being
      • gene amplification of an oncogene (frequently seen in Her-2/neu)
      • overexpression of the respective gene due to an altered Methylation pattern, mutations
      • altered properties of a transcription factor, a promotor or another factor which leads to an upregulation of the expression level of the said agent.
  • In a preferred embodiment of the present invention, it is provided that the at least one gene of interest is correlated with a negative Estrogen receptor status.
  • The applicants have, in various studies, analyzed breast tumors with ESR1 negative and Her-2/neu negative status as determined with Immunochistochemistry (IHC) and/or Fluorescence In situ Hybridization (FISH). Core needle biopsy specimen of these tumors was analyzed on the DNA and RNA level by quantitative PCR, RT-PCR and array technologies.
  • During this process, the applicants have, surprisingly, identified a number of candidate genes which are correlated with, and are thus predictive for, subgroups of Estrogen receptor negative tumors (ESR−).
  • The following genes were identified to be useful for the discrimination of ESR1 positive tumors (IHC status 4, i.e. ESR status as determined with Immunohistochemistry) from ESR1 negative tumors (IHC status 0) by having high expression levels, high variance and fold change levels as identified in fresh tumor tissue.
  • TABLE 1
    Genes that can be used to discriminate ESR1 positive
    tumors from ESR1 negative tumors
    Gene Map Locus RefSeq
    Symbol Location Link OMIM UniGene Transcript
    AKR7A3 chr1p35.1-p36.23 22977 608477 Hs.6980 NM_012067
    ALCAM chr3q13.1 214 601662 Hs.150693 NM_001627
    AR chrXq11.2-q12 367 313700 Hs.496240 NM_000044,
    NM_001011645
    ASPN chr9q22 54829 608135 Hs.435655 NM_017680
    BCL2 chr18q21.33|18q21.3 596 151430 Hs.150749 NM_000633,
    NM_000657
    C6orf211 chr6q25.1 79624 Hs.15929 NM_024573
    CA12 chr15q22 771 603263 Hs.210995 NM_001218,
    NM_206925
    CCND1 chr11q13 595 168461 Hs.523852 NM_053056
    CDC2 chr10q21.1 983 116940 Hs.334562 NM_001786,
    NM_033379
    CEACAM6 chr19q13.2 4680 163980 Hs.466814 NM_002483
    CELSR1 chr22q13.3 9620 604523 Hs.252387 NM_014246
    CHI3L1 chr1q32.1 1116 601525 Hs.382202 NM_001276
    COL4A5 chrXq22 1287 303630 Hs.369089 NM_000495,
    NM_033380,
    NM_033381
    CPE chr4q32.3 1363 114855 Hs.75360 NM_001873
    CRAT chr9q34.1 1384 600184 Hs.12068 NM_000755,
    NM_004003,
    NM_144782
    CXCL9 chr4q21 601704 Hs.77367
    CX3CR1 chr3p21|3p21.3 1524 601470 Hs.78913 NM_001337
    CXCL10 chr4q21 3627 147310 Hs.413924 NM_001565
    DNAJC12 chr10q22.1 56521 606060 Hs.260720 NM_021800,
    NM_201262
    ERBB2/ chr17q11.2-q12|
    Her-2/neu 17q21.1
    ERBB4 chr2q33.3-q34 2066 600543 Hs.390729 NM_005235
    ESR1 chr6q25.1 2099 133430 Hs.208124 NM_000125
    FBP1 chr9q22.3 2203 229700 Hs.494496 NM_000507
    FLJ20152 chr5p15.1 54463 Hs.481704 NM_019000
    FOS chr14q24.3 2353 164810 Hs.25647 NM_005252
    FOXA1 chr14q12-q13 3169 602294 Hs.163484 NM_004496
    GATA3 chr10p15 2625 131320 Hs.524134 NM_001002295,
    NM_002051
    IGF2 chr11p15.5 3481 147470 Hs.523414 NM_001007139
    ITPR1 chr3p26-p25 3708 147265 Hs.374613 NM_002222
    JMJD2B chr19p13.3 23030 Hs.371013 NM_015015
    KIAA0303 chr5q12.3 23227 Hs.133539 XM_291141
    KIAA0882 chr4q31.21 23158 Hs.480819 NM_015130
    KIF5C chr2q23.1 3800 604593 Hs.435557 XM_377774
    KRT23 chr17q21.2 25984 606194 Hs.9029 NM_015515,
    NM_173213
    KRT5 chr12q12-q13 3852 148040 Hs.433845 NM_000424
    KRT6B chr12q12-q13 3854 148042 Hs.524438 NM_005555
    MAPT chr17q21.1 4137 157140 Hs.101174 NM_005910,
    NM_016834,
    NM_016835,
    NM_016841
    MLPH chr2q37.3 79083 606526 Hs.102406 NM_024101
    MMP7 chr11q21-q22 4316 178990 Hs.2256 NM_002423
    NAT1 chr8p23.1-p21.3 9 108345 Hs.155956 NM_000662
    PHGDH chr1p12 26227 606879 Hs.487296 NM_006623
    PROM1 chr4p15.32 8842 604365 Hs.479220 NM_006017
    RARRES1 chr3q25.32 5918 605090 Hs.131269 NM_002888,
    NM_206963
    RRM2 chr2p25-p24 6241 180390 Hs.226390 NM_001034
    RRM2 chr2p25-p24 6241 180390 Hs.226390 NM_001034
    S100A8 chr1q21 6279 123885 Hs.416073 NM_002964
    SCNN1A chr12p13 6337 600228 Hs.130989 NM_001038
    SCUBE2 chr11p15.3 57758 Hs.523468 NM_020974
    SEMA3C chr7q21-q31 10512 602645 Hs.269109 NM_006379
    SFRP1 chr8p12-p11.1 6422 604156 Hs.213424 NM_003012
    SLC7A5 chr16q24.3 8140 600182 Hs.513797 NM_003486
    SLC7A8 chr14q11.2 23428 604235 Hs.22891 NM_012244,
    NM_182728
    SLPI chr20q12 6590 107285 Hs.517070 NM_003064
    SOCS2 chr12q 8835 605117 Hs.485572 NM_003877
    SOD2 chr6q25.3 6648 147460 Hs.487046 NM_000636
    SPDEF chr6p21.3 25803 608144 Hs.485158 NM_012391
    STC2 chr5q35.1 8614 603665 Hs.233160 NM_003714
    TFF1 chr21q22.3 7031 113710 Hs.162807 NM_003225
    TFF3 chr21q22.3 7033 600633 Hs.82961 NM_003226
    TOP2A chr17q21-q22 7153 126430 Hs.156346 NM_001067
    TPX2 chr20q11.2 22974 605917 Hs.244580 NM_012112
    TRIM29 chr11q22-q23 23650 Hs.504115 NM_012101,
    NM_058193
    TSPAN-1 chr1p34.1 10103 Hs.38972 NM_005727
    VAV3 chr1p13.3 10451 605541 Hs.267659 NM_006113
  • The terms “MapLocation, LocusLink, Unigene and OMIM” relate to databases in which the respective proteins are listed under the given access number. These databases can be accessed over the NCBI server.
  • Out of these, preferred genes are the following:
  • TABLE 2
    Preferred genes that can be used to discriminate ESR1 positive tumors from
    ESR1 negative tumors
    Gene RefSeq
    Symbol Map Location LocusLi OMIM UniGene Transcript
    ALCAM chr3q13.1 214 601662 Hs.150693 NM_001627
    ASPN chr9q22 54829 608135 Hs.435655 NM_017680
    BCL2 chr18q21.33|18q21.3 596 151430 Hs.150749 NM_000633,
    NM_000657
    CCND1 chr11q13 595 168461 Hs.523852 NM_053056
    CDC2 chr10q21.1 983 116940 Hs.334562 NM_001786,
    NM_033379
    CEACAM6 chr19q13.2 4680 163980 Hs.466814 NM_002483
    CELSR1 chr22q13.3 9620 604523 Hs.252387 NM_014246
    CHI3L1 chr1q32.1 1116 601525 Hs.382202 NM_001276
    COL4A5 chrXq22 1287 303630 Hs.369089 NM_000495,
    NM_033380,
    NM_033381
    CPE chr4q32.3 1363 114855 Hs.75360 NM_001873
    CRAT chr9q34.1 1384 600184 Hs.12068 NM_000755,
    NM_004003,
    NM_144782
    CXCL9
    CXCL10 chr4q21 3627 147310 Hs.413924 NM_001565
    DNAJC12 chr10q22.1 56521 606060 Hs.260720 NM_021800,
    NM_201262
    FLJ20152 chr5p15.1 54463 Hs.481704 NM_019000
    FOS chr14q24.3 2353 164810 Hs.25647 NM_005252
    ITPR1 chr3p26-p25 3708 147265 Hs.374613 NM_002222
    JMJD2B chr19p13.3 23030 Hs.371013 NM_015015
    KIF5C chr2q23.1 3800 604593 Hs.435557 XM_377774
    KRT23 chr17q21.2 25984 606194 Hs.9029 NM_015515,
    NM_173213
    KRT5 chr12q12-q13 3852 148040 Hs.433845 NM_000424
    KRT6B chr12q12-q13 3854 148042 Hs.524438 NM_005555
    LOC492304 chr11p15.5 3481 147470 Hs.523414 NM_001007139
    MAPT chr17q21.1 4137 157140 Hs.101174 NM_005910,
    NM_016834,
    NM_016835,
    NM_016841
    MAST4 chr5q12.3 23227 Hs.133539 XM_291141
    MLPH chr2q37.3 79083 606526 Hs.102406 NM_024101
    MMP7 chr11q21-q22 4316 178990 Hs.2256 NM_002423
    PHGDH chr1p12 26227 606879 Hs.487296 NM_006623
    PROM1 chr4p15.32 8842 604365 Hs.479220 NM_006017
    RARRES1 chr3q25.32 5918 605090 Hs.131269 NM_002888,
    NM_206963
    S100A8 chr1q21 6279 123885 Hs.416073 NM_002964
    SCUBE2 chr11p15.3 57758 Hs.523468 NM_020974
    SLC7A5 chr16q24.3 8140 600182 Hs.513797 NM_003486
    SLPI chr20q12 6590 107285 Hs.517070 NM_003064
    SOCS2 chr12q 8835 605117 Hs.485572 NM_003877
    SOD2 chr6q25.3 6648 147460 Hs.487046 NM_000636
    STC2 chr5q35.1 8614 603665 Hs.233160 NM_003714
    TFF1 chr21q22.3 7031 113710 Hs.162807 NM_003225
    TOP2A chr17q21-q22 7153 126430 Hs.156346 NM_001067
    TRIM29 chr11q22-q23 23650 Hs.504115 NM_012101,
    NM_058193
    TSPAN1 chr1p34.1 10103 Hs.38972 NM_005727
  • The applicants have analysed these genes and were able to assign the said genes to given biological motifs which are correlated with, and are thus predictive for, subgroups of Estrogen receptor (ESR) negative tumors. By way of illustration and not by limitation these motifs may be selected from the group comprising at least
      • extracellular matrix degradation (Table 3),
      • growth factor signaling (Table 4),
      • immune cell infiltration (Table 5) and/or
      • basal markers (Table 6).
  • Extracellular Matrix degradation is frequently caused by Matrix Metalloproteinases. For this reason, most preferred genes are part of the Matrix Metalloproteinase gene family, and the Keratin gene family, which both tend to exhibit bimodal distribution of expression values. Such genes are, for example
      • Matrix Metallo Proteinases (MMP), particularly MMP1, MMP3, MMP7, MMP9, MMP11 and MMP12, most preferred MMP7
  • TABLE 3
    Preferred genes related genes related to
    extracellular matrix degradation
    Gene RefSeq
    Symbol MapLocation LocusLink OMIM UniGene Transcript
    MMP1 chr11q22.3 120353 Hs.83169
    MMP3 chr 11q22.3 185250 Hs.375129
    MMP7 chr 11q21-q22 178990 Hs.2256
    MMP9 chr 20q11.2- 120361 Hs.297413
    q13.1
    MMP11 chr 22q11.2- 185261 Hs.143751
    q11.23
    MMP12 chr 11q22.3 601046 Hs.1695
    Hs.645661
  • Genes related to growth factor signalling may for example encode for hormone receptors, growth factor receptors, growth factor ligands, inhibitors and the like. Such genes comprise, for example, genes encoding a receptor from the ErbB-family, or a gene correlated with the Progesterone receptor (PGR) status in the said sample.
  • TABLE 4
    Preferred genes related related to growth factor signalling
    Gene Map RefSeq
    Symbol Location Entrez LocusLink OMIM UniGene Transcript
    PGR chr11q22- 607311 Hs.368072
    q23
    ESR chr6q25.1 133430 Hs.208124
    EGFR/ErbB1 chr7p12 131550 Hs.488293
    VEGFR chr4q11- 191306 Hs.479756
    q12
    ErbB2/ chr17q11.2- 164870 Hs.446352
    Her-2/neu q12;
    17q21.1
    ErbB4 chr2q33.3- 600543 Hs.390729
    q34
    C-Kit chr 4q11- 164920 Hs.479754
    q12
    PDGFRA chr 4q11- 173490 Hs.74615
    q13
    PDGFRB chr 5q31- 173410 Hs.509067
    q32
    PDGFRC chr 4q32 608452 Hs.570855
    C-MET chr 7q31 164860 Hs.132966
  • Genes related to immune cell infiltration may be selected from the following table (listing is not exclusive):
  • TABLE 5
    Preferred genes related to immune cell infiltration
    Gene Map Locus
    Symbol Location Entrez Link OMIM UniGene RefSeq
    CD79A chr19q13.2 NM_001783 973 112205 Hs.79630 NM_001783,
    NM_021601
    CD79B chr17q23 NM_000626 974 147245 Hs.89575 NM_000626,
    NM_021602
    CD83 chr6p23 NM_004233 9308 604534 Hs.484703 NM_004233
    IGBP1 chrXq13.1- NM_001551 3476 300139 Hs.496267 NM_001551
    q13.3
    IGH@ chr14q32.33 S65761 3492 Hs.510635
    IGH@, chr14q32.33 U80164
    IGHG1
    IGH@, chr14q32.33 M87789 3502 147120 Hs.525646
    IGHG1,
    IGHG2, IGHM
    IGH@, chr14q32.33, BG340548 283650 Hs.366 —,
    IGHG1, chr16p11.2 XM_372632
    IGHG2,
    IGHM,
    LOC390714,
    MGC27165
    IGHA2, chr14q32.33 S55735 283650 Hs.366
    MGC27165
    IGHD chr14q32.33 AI858004 3495 147170 Hs.439852
    IGHD chr14q32.33 AJ275469 Hs.525874
    IGHD chr14q32.33 BG340670 Hs.448957
    IGHD chr14q32.33 AW134608 3495 147170 Hs.439852
    IGHD, IGHG1, chr14q32.33 M21388 Hs.112610
    IGHM,
    MGC27165
    IGHG1 chr14q32.33 M24668 Hs.531234
    IGHG1 chr14q32.33 L23519 Hs.449011
    IGHG1 chr14q32.33 L14454 3507 147020 Hs.525647
    IGHG1 chr14q32.33 L14455 Hs.497707
    IGHG1 chr14q32.33 L14456 Hs.497707
    IGHG1 chr14q32.33 AJ225092
    IGHG1 chr14q32.33 X58397 Hs.532509
    IGHG1 chr14q32.33 AJ275397
    IGHG1 chr14q32.33 U92706
    IGHG1 chr14q32.33 S74639 Hs.497707
    IGHG1, chr14q32.33 AJ275408
    IGHG3
    IGHG1, IGHM chr14q32.33 U80139
    IGHG1, chr14q32.33 AJ239383 283650 Hs.366
    IGHM,
    MGC27165
    IGHG1, chr14q32.33, M87268 Hs.448957 —,
    LOC390714 chr16p11.2 XM_372632
    IGHG1, chr14q32.33, AB035175 —,
    LOC390714 chr16p11.2 XM_372632
    IGHM chr14q32.33 BC001872 3495 147170 Hs.439852
    IGHM chr14q32.33 M24669 3495 147170 Hs.4398502
    IGHM chr14q32.33 L23518 3495 147170 Hs.439852
    IGHM chr14q32.33 X17115 3495 147170 Hs.439852
    IGHM chr14q32.33 BF002659 3495 147170 Hs.439852
    IGHMBP2 chr11q13.2- L14754 3508 600502 Hs.503048 NM_002180
    q13.4
    IGHMBP2 chr11q13.2- AF052128 3508 600502 Hs.503048 NM_002180
    q13.4
    IGJ chr4q21 AV733266 3512 147790 Hs.381568 NM_144646
    IGKC chr2p12 X72475 Hs.512130
    IGKC chr2p12 BC005332 3514 147200 Hs.449621
    IGKC chr2p12 M63438 3514 147200 Hs.449621
    IGKV1D-13 chr2p12 AW408194 28902 Hs.390427
    IGL@ chr22q11.1- X93006 Hs.449598
    q11.2
    IGL@, IGLC2 chr22q11.1- X57812 28831, Hs.449585
    q11.2, 3535,
    chr22q11.2 3538
    IGL@, IGLC2 chr22q11.1- AA680302 3546 147240 Hs.449587
    q11.2,
    chr22q11.2
    IGL@, IGLC2 chr22q11.1- AV698647 Hs.458262
    q11.2,
    chr22q11.2
    IGLC2 chr22q11.2 M87790 Hs.458262
    IGLC2 chr22q11.2 H53689 Hs.449582
    IGLC2 chr22q11.2 AF043586 28831, Hs.449585
    3535,
    3538
    IGLC2 chr22q11.2 D87021 96610 Hs.449601
    IGLC2 chr22q11.2 AJ249377 28831 Hs.517455
    IGLC2, IGLJ3 chr22q11.1- AF047245 Hs.537013
    q11.2,
    chr22q11.2
    IGLC2, IGLJ3 chr22q11.1- AF234254 28831 Hs.517453
    q11.2,
    chr22q11.2
    IGLJ3 chr22q11.1- AB001733 28831 Hs.517453
    q11.2
    IGLJ3 chr22q11.1- AB014341 28831 Hs.517453
    q11.2
    IGLL1 chr22q11.23 NM_020070 3543 146770 Hs.348935 NM_020070,
    NM_152855
    IGLL1, chr22q11.23 AL022324 3543 146770 Hs.348935 NM_020070,
    LOC91316 NM_152855,
    XM_498877
    IGLV6-57 chr22q11.2 AI952772 3546 147240 Hs.449587
    IGSF1 chrXq25 NM_001555 3547 300137 Hs.22111 NM_001555,
    NM_205833
    IGSF2 chr1p13 NM_004258 9398 604516 Hs.74115 NM_004258
    IGSF3 chr1p13 AB007935 3321 603491 Hs.171057 NM_001007237,
    NM_001542
    IGSF4 chr11q23.2 NM_014333 23705 605686 Hs.370510 NM_014333
    IGSF4 chr11q23.2 AL519710 23705 605686 Hs.370510 NM_014333
    IGSF4 chr11q23.2 AF132811 23705 605686 Hs.370510 NM_014333
    IGSF4B chr1q21.2- AF062733 57863 Hs.365689 NM_021189
    q22
    IGSF4B chr1q21.2- AI564838 57863 Hs.365689 NM_021189
    q22
    IGSF4B chr1q21.2- AL050219 57863 Hs.365689 NM_021189
    q22
    IGSF4B chr1q21.2- AL050219 57863 Hs.365689 NM_021189
    q22
    IGSF4B chr1q21.2- AI951798, 57863 Hs.365689 NM_021189
    q22 AU129642
    IGSF4C chr19q13.31 AC005525 199731 Hs.370984 NM_145296
    IGSF4C chr19q13.31 AC005525 199731 Hs.370984 NM_145296
    IGSF4C chr19q13.31 AW204383 199731 Hs.370984 NM_145296
    IGSF6 chr16p12-p13 NM_005849 10261 606222 Hs.530902 NM_005849
    ILT10 chr19q13.4 NM_024317 79166 Hs.202680 NM_024317
    ILT7 chr19q13.4 AF041261 23547 607517 Hs.406708 NM_012276
    ISLR chr15q23-q24 NM_005545 3671 602059 Hs.513022 NM_005545,
    NM_201526
    KIR2DL1 chr19q13.4 U24078 3802 604936 Hs.512572 NM_014218
    KIR2DL2 chr19q13.4 L76669 3812 604947 Hs.380156 NM_014219
    KIR2DL3 chr19q13.4 AF022048 3804 604938 Hs.512573 NM_014511,
    NM_015868
    KIR2DL4 chr19q13.4 NM_002255 3805 604945 Hs.166085 NM_002255
    KIR2DL4 chr19q13.4 AF276292 3805 604945 Hs.166085 NM_002255
    KIR2DL4 chr19q13.4 AF002256 3805 604945 Hs.166085 NM_002255
    KIR2DL5 chr19p13.3 AF217487 115653, Hs.278457 NM_020535
    3811
    KIR2DL5, chr19p13.3, AJ000190 115653, Hs.278457 NM_006737,
    KIR3DL2, chr19q13.4, 3811 NM_020535,
    KIR3DL3 chr19q13.42 NM_153443
    KIR2DS1 chr19q13.4 NM_014512 3805 604945 Hs.166085 NM_014512
    KIR2DS2 chr19q13.4 L76668 3812 604947 Hs.380156 NM_012312
    KIR2DS3 chr19q13.4 NM_012313 3812 604947 Hs.380156 NM_012313
    KIR2DS4 chr19q13.4 AF135564 3806 604952 Hs.512574 NM_012314
    NM_178228
    KIR2DS5 chr19q13.4 NM_014513 3812 604947 Hs.380156 NM_014513
    KIR3DL1 chr19q13.4 AF262973 3812 604947 Hs.380156 NM_013289
    KIR3DL2 chr19q13.4 L76666 3812 604947 Hs.380156 NM_006737
    KIR3DL2 chr19q13.4 NM_006737 3812 604947 Hs.380156 NM_006737
    KIR3DL2 chr19q13.4 AF263617 3812 604947 Hs.380156 NM_006737
    KIR3DL2 chr19q13.4 X93596 3812 604947 Hs.380156 NM_006737
    KIR3DL3 chr19q13.42 AC006293 3804 604938 Hs.512573 NM_153443
    LILRA1 chr19q13.4 NM_006863 10859, Hs.534393 NM_006863
    11024
    LILRA1 chr19q13.4 AF025529 10859, Hs.534393 NM_006863
    11024
    LILRA2 chr19q13.4 NM_006866 11027 604812 Hs.534394 NM_006866
    LILRA2 chr19q13.4 U82278 11027 604812 Hs.534394 NM_006866
    LILRA2 chr19q13.4 U82276 11027 604812 Hs.534394 NM_006866
    LILRA2 chr19q13.4 U82277 11027 604812 Hs.534394 NM_006866
    LILRA3 chr19q13.4 NM_006865 11026 604818 Hs.113277 NM_006865
    LILRB1 chr19q13.4 NM_006669 10859 604811 Hs.149924 NM_006669
    LILRB1 chr19q13.4 AF009007 10859 604811 Hs.149924 NM_006669
    LILRB2 chr19q13.4 NM_005874 10990 604814 Hs.306230 NM_005874
    LILRB2, chr19q13.4 AF004231 10990 604814 Hs.306230 NM_005874
    LILRB6 NM_024318
    LILRB3 chr19q13.4 AF009635 10288, Hs.515601 NM_006864
    11025,
    79168
    LILRB3 chr19q13.4 AF009634 10288, Hs.515601 NM_006864
    11025,
    79168
    LILRB3 chr19q13.4 AF009643 10288, Hs.515601 NM_006864
    11025,
    79168
    LILRB3 chr19q13.4 AF009644 10288, Hs.515601 NM_006864
    11025,
    79168
    LILRB4 chr19q13.4 U82979 11006 604821 Hs.67846 NM_006847
    LILRB5 chr19q13.4 NM_006840 10990 604814 Hs.306230 NM_006840
    LILRB6 chr19q13.4 NM_024318 10288, Hs.515601 NM_024318
    11025,
    79168
    LOC440361 chr16p11.2 AJ275383 XM_496145
    LOC91316 chr22q11.23 AA398569 91316 Hs.407693 XM_498877
    LOC91316 chr22q11.23 AU158566 91316 Hs.407693 XM_498877
    LOC91316 chr22q11.23 AK025313 XM_498877
    LOC91316 chr22q11.23 L02326 XM_498877
    LRIG1 chr3p14 AB050468 26018 608868 Hs.518055 NM_015541
    LRIG2 chr1p13.1 NM_014813 9860 608869 Hs.448972 NM_014813
    PIGR chr1q31-q41 NM_002644 5284 173880 Hs.497589 NM_002644
    SEMA3A chr7p12.1 NM_006080 10371 603961 Hs.252451 NM_006080
    SEMA3B chr3p21.3 NM_004636 7869 601281 Hs.82222 NM_001005914,
    NM_004636
    SEMA3C chr7q21-q31 AI962897 10512 602645 Hs.269109 NM_006379
    SEMA3C chr7q21-q31 NM_006379 10512 602645 Hs.269109 NM_006379
    SEMA3D chr7q21.11 AA343027 223117 Hs.201340 NM_152754
    SEMA3D chr7q21.11 AU145680 223117 Hs.201340 NM_152754
    SEMA3F chr3p21.3 U38276 6405 601124 Hs.32981 NM_004186
    SEMA3F chr3p21.3 NM_004186 6405 601124 Hs.32981 NM_004186
    SEMA3F chr3p21.3 U38276 6405 601124 Hs.32981 NM_004186
    SEMA4A chr1q22 NM_022367 64218 607292 Hs.408846 NM_022367
    SEMA4C chr2q11.2 AI949392 54910 604462 Hs.516220 NM_017789
    SEMA4C chr2q11.2 NM_017789 54910 604462 Hs.516220 NM_017789
    SEMA4D chr9q22-q31 NM_006378 10507 601866 Hs.511748 NM_006378
    SEMA4F chr2p13.1 NM_004263 10505 603706 Hs.25887 NM_004263
    SEMA4F chr2p13.1 AL136552 10505 603706 Hs.25887 NM_004263
    SEMA4G chr10q24.32 NM_017893 57715 Hs.444359 NM_017893
    SEMA7A chr15q22.3- AF071542 8482 607961 Hs.24640 NM_003612
    q23
    TCF3 chr19p13.3 AA768906, 6929 147141 Hs.371282 NM_003200
    M31523
    TCF3 chr19p13.3 AI655986, 6929 147141 Hs.371282 NM_003200
    M31523
    TCF3 chr19p13.3 M31523 6929 147141 Hs.371282 NM_003200
    TCF3 chr19p13.3 M31222 6929 147141 Hs.371282 NM_003200
    TCF3 chr19p13.3 BE962186 6929 147141 Hs.371282 NM_003200
    TCF3 chr19p13.3 AW062341, 6929 147141 Hs.371282 NM_003200
    BG393795
    TCF3 chr19p13.3 X52078 6929 147141 Hs.371282 NM_003200
    TCF3 chr19p13.3 AL117663 6929 147141 Hs.371282 NM_003200
    TIE1 chr1p34-p33 NM_005424 7075 600222 Hs.78824 NM_005424
    TTID chr5q31 NM_006790 9499 604103 Hs.84665 NM_006790
    VSIG4 chrXq12- NM_007268 11326 300353 Hs.8904 NM_007268
    q13.3
    CXCL9
    CXCL10 chr4q21 147310 Hs.413924 NM_001565
    IGHM chr14q32.33 147020 Hs.510635
    MMP9 chr20q11.2- 120361 Hs.297413
    q13.1
  • Genes related to basal markers (the term “basal markers” is derived from the appearance of the respective cells, which is similar to basal cells) may be selected from the following table (listing is not exclusive):
  • TABLE 6
    Preferred genes related to basal markers
    Gene Locus RefSeq
    Symbol Map Location Link OMIM UniGene Transcript
    KRT5 chr12q12-q13 148040 Hs.694210
    Hs.694210
    KRT6A chr12q12-q13 148041 Hs.433845
    KRT6B chr12q12-q13 148042 Hs.433845
    KRT14 chr17q12-q21 148066 Hs.654380
    KRT23 chr17q21.2 606194 Hs.9029
    KRT17 chr17q12-q21 148069 Hs.2785
    MLPH chr2q37.3 79083 606526 Hs.102406 NM_024101
  • Out of these, most preferred genes are the following:
  • TABLE 7a
    Preferred genes in the context of the present
    invention
    Gene Symbol Biological motif
    ERBB2/ growth factor signallling
    Her-2/neu
    MMP7 extracellular matrix degradation
    MMP1 extracellular matrix degradation
    PGR growth factor signallling
    ESR1 growth factor signallling
    MLPH extracellular matrix
    degradation/basal marker
    IGHM immune cell infiltration
    C-Kit growth factor signalling
    C-MET growth factor signalling
    EGFR growth factor signalling
  • Out of these, MMP1, MLPH, ESR1 and Her-2/neu are subject of a most preferred embodiment of the invention.
  • Furthermore, it is preferred that at least one mode of treatment for which prediction is sought is a neoadjuvant chemotherapy and/or targeted therapy. These two types of therapy are particularly promising in ESR negative (ESR−) tumors which are not susceptible to endocrine treatment with, for example, tamoxifen.
  • The terms “neoadjuvant therapy”, “chemotherapy” and “targeted therapy” have been defined above.
  • Said chemotherapy may comprise the administration of at least one agent selected from the group consisting of Cyclophosphamid (Endoxan®, Cyclostin®). Adriamycin (Doxorubicin) (Adriblastin®), BCNU (Carmustin) (Carmubris®), Busulfan (Myleran®), Bleomycin (Bleomycin®), Carboplatin (Carboplat®), Chlorambucil (Leukeran®), Cis-Platin (Cisplatin®), Platinex (Platiblastin®), Dacarbazin (DTIC®; Detimedac®), Docetaxel (Taxotere®), Epirubicin (Farmorubicin®), Etoposid (Vepesid®), 5-Fluorouracil (Fluroblastin®, Fluorouracil®), Gemcitabin (Gemzar®), Ifosfamid (Holoxan®), Interferon alpha (Roferon®), Irinotecan (CPT 11, Campto®), Melphalan (Alkeran®), Methotrexat (Methotrexat®, Farmitrexat®), Mitomycin C (Mitomycin®), Mitoxantron (Novantron®), Oxaliplatin (Eloxatine®), Paclitaxel (Taxol®), Prednimustin (Sterecyt®), Procarbazin (Natulan®), Pemetrexed (Alimta®), Ralitrexed (Tomudex®), Topotecan (Hycantin®), Trofosfamid (Ixoten®), Vinblastin (Velbe®), Vincristin (Vincristin®), Vindesin (Eldisine®) and/or Vinorelbin (Navelbine®).
  • In particularly preferred embodiments, the following agents and equitoxic modifications thereof are used alone or in combination:
      • Taxanes (e.g. Docetaxel, Paclitaxel)
      • Anthracyclins (e.g. Doxorubicine, Epirubicine, Daunorubicin, Mitoxanthrone, Idarubicin or modifications thereof as e.g. pegylated anthracyclins)
      • Cyclophosphamide
      • Tubulin modifying agents (e.g. vinorelbine)
      • 5′FU based regimen (including Capecitabine)
      • Antibody based regimen (e.g. Avastin®, Erbitux®, Herceptin®)
      • Small molecule inhibitors (e.g. Tykerb®, Tarceva®, Iressa®, Sutent®, Nexavar®)
  • Recent studies by the inventors showed furthermore that an overexpression of MMP1 and/or MLPH is frequently correlated with irregularities in the expression of the breast cancer gene BRCA1. BRCA1 (breast cancer 1, early onset) belongs to a class of genes known as tumor suppressors, which maintain genomic integrity to prevent uncontrolled proliferation. The multifactorial BRCA1 protein product is involved in DNA damage repair, ubiquitination, transcriptional regulation as well as other functions. Genetic variations leading to a BRCA1 deficiency have been implicated in a number of hereditary cancers, namely breast, ovarian and prostate, as an important DNA repair system is lost which otherwise would prevent the accumulation of mutations fostering tumor genesis.
  • Genetic variations of BRCA1 comprise, for example, (i) an altered methylation pattern, (ii) a mutation in the gene (i.e. SNP or gene rearrangements), or (iii) an alteration of the respective promoter.
  • BRCA1 deficient tumors are known to be quickly growing tumors which are comparatively resistant against chemotherapy. A novel treatment for these tumors is inhibitors of Poly (ADP-ribose) polymerase 1 (PARP1). PARP1 plays a role in repair of single-stranded DNA (ssDNA) breaks. In the absence of PARP1, when these breaks are encountered during DNA replication, the replication fork stalls and double-strand DNA (dsDNA) breaks accumulate. These dsDNA breaks are repaired via homologous recombination (HR) repair. If the HR pathway is functioning, PARP1 deficient mutants do not show an unhealthy phenotype. However, BRCA1 is necessary for the HR pathway to work properly. Therefore, cells which are deficient in BRCA1 are highly sensitive to PARP1 inhibition or knock-down, resulting in cell death by apoptosis, in stark contrast to cells with at least one functionally intact copy of BRCA1.
  • This means that BRCA1 deficient mutants are likely to become prone to apoptosis in case they are also deficient for PARP1, or PARP1 is inhibited by a respective drug, i.e. a PARP1 inhibitor (see above); preferably if the latter is combined with chemotherapy, e.g. taxane administration. This means, in turn, that PARP1 inhibition therapy is a promising treatment for BRCA1 deficient tumors.
  • Current tests for BRCA1 deficiencies, as for example performed within clinical trials to test the efficacy of KU-0059436 (PARP1 inhibitor manufactured by Astra Zeneca), comprise only those deficiencies caused by mutation of the BRCA1 gene (i.e. variant (ii)), as these tests perform sequence analysis or use sequence specific probes. BRCA1 deficiencies due to altered methylation patterns, or an alteration of the respective promoter, are not detected by these tests.
  • Furthermore, direct determination of the expression level of BRCA1 is complex, as the median expression level of BRCA1 is downregulated by approximately 2 fold, which is in the range of assay variabilities for some gene expression determination methods (e.g. RT-PCR), and is highly dependent on the share of tumor cells in the respective sample.
  • In contrast thereto, the inventors found that simultaneous detection of MMP7 and/or MLPH reveals as well the latter variants discussed above (i.e. variant (i) and (iii), and will thus help to provide adequate treatment for those patients which have a BRCA1 deficiency that is not caused by mutation of the BRCA1 gene itself. The inventors estimate that, by the said simultaneous detection of MMP7 and/or MLPH, between 2 to 5 times more BRCA1 deficient tumors can be detected than with the current tests, which means that up to 5 times more patients can be provided with adequate PARP1 inhibition treatment.
  • Interestingly, the said correlation between irregularities in BRCA1 expression and the gene expression level of other genes is not only valid for MMP7 and MLPH, but also for MMP1, ESR1, PGR, Her-2/neu, IGHM, C-Kit, C-MET and EGFR, and other genes identified in this application.
  • Moreover, the inventors have demonstrated that MMP7 positive tumors were frequently found to have decreased expression of RB1 (Retinoblastoma 1), i.e. there seems to be a correlation between MMP7 overexpression and RB1 deficiency. RB1 is not only a negative regulator of the cell cycle (indeed, it has been the first tumor suppressor gene identified), but also involved in the stabilization of constitutive chromatin.
  • Again, RB1 deficient tumors are particularly sensitive towards intensified chemotherapy and also inclusion of PARP1 inhibitors, namely for the same reasons as mentioned in the context of BRCA1. This means that, for example, PARP1 inhibition and addition of taxanes is beneficial in these tumors, which otherwise have a poor outcome.
  • As for BRCA1, direct determination of the expression level of RB1 is complex, as the median expression level of RB1 is downregulated by approximately 2 fold, which is in the range of assay variabilities for some gene expression determination methods (e.g. RT-PCR), and is highly dependent on the share of tumor cells in the respective sample.
  • Again, it is thus beneficial to measure the gene expression of a gene correlated with RB1 irregularities. Interestingly, the said correlation between irregularities in RB1 expression and the gene expression level of other genes is not only valid for MMP7 and MLPH, but also for MMP1, ESR1, PGR, Her-2/neu, IGHM, C-Kit, C-MET and EGFR, and other genes identified in this application.
  • The above phenomena apply as well to the CCND1 gene (Cyclin D1 (PRAD1). The CCND1 protein contributes to the progression of the cell cycle in the G1/S checkpoint. CCND1 overexpression (for instance as a consequence of CCND1 amplification) might result in loss of control over genetic damage at this point and in an accumulation of chromosomal aberrations.
  • The inventors found, during their studies related to this invention, that the detection of RB1, BRCA1 and/or CCND1 irregularities and/or deficiencies in basal type tumors, as identified by e.g. MMP7 and/or MLPH expression levels, renders such tumors particularly sensitive to defined therapeutic interventions. The said genes are listed in the following table:
  • TABLE 7b
    Negatively
    correleated/
    Gene Map Locus RefSeq coexpressed
    Symbol Location Link OMIM UniGene Transcript with
    RB1 13q14.2 180200 Hs.408528 MMP7/MLPH
    BRCA1 17q21 113705 Hs.194143 MMP7/MLPH
    CCND1 11q13 168461 Hs.523852 MMP7/MLPH
  • In a preferred embodiment, it is thus provided that the mode of treatment for which prediction is sought is a therapy directed to the inhibition of homologous recombination repair. This is, for example, being done be determination of MMP7 and/or MLPH, which are reciprocally correlated with RB1, BRCA1 and CCND1. This means that a high expression level of MMP7 and/or MLPH is an indication for a therapy directed to the inhibition of homologous recombination repair. Examples for such therapy are Inhibitors of Poly (ADP-ribose) polymerase 1 (PARP1), like AZD2281 (KU-0059436), FR247304, AG14361, GPI 15427, GPI 16539, caffeine metabolites like 1,7-dimethylxanthine, 3-methylxanthine 1-methylxanthine, theobromine and theophylline, and others.
  • In yet another preferred embodiment of the present invention, it is provided that the method further comprises the steps of
      • e) determining the expression level of at least one gene correlated and/or coexpressed with a receptor from the ErbB-family in the said sample, and/or
      • f) determining the expression level of at least one gene correlated and/or coexpressed with the Progesterone receptor (PGR) status in the said sample.
  • In this regard we have found that the expression of Her-2/neu is quite often negatively correlated with EGFR expression. EGFR expression is particularly prominent in tumors exhibiting low expression of Her-2/neu, ESR1 and PGR. However, the exact and robust determination of EGFR expression is critical both on protein and mRNA level. It is particularly difficult to determine a clear cut threshold to reliably discriminate between high and low expressing breast tumors, in part because of a narrow dynamic range of EGFR expression and technical variations due to assay platform or variable tissue composition in independent tumor samples of the same tumor.
  • In contrast, the determination of MMP7, as an example, is robust and more reliable, as the dynamic range is broader and the data distribution is almost bimodal, enabling to define a biologically and clinically meaningful threshold between high and low expressing tumors.
  • Moreover, we have found that high expression of MMP7 excludes high expression of Her-2/neu, ESR1 and PGR (=“basal like tumors”). Still not all, but about 50% of the basal like tumors express MMP7. Most preferred is the combination of MMP7 with MLPH, which trends to exhibit bimodal distribution of expression values, while being strongly associated with ESR1 expression.
  • There is evidence for a correlation between ESR and growth factor receptor pathways, such as the ErbB pathway. The ESR can be phosphorylated at the serine-118 position within AF-1 by the MAPKs ERK1 and ERK2, which are downstream components of the Her-2/neu signalling pathway, the latter being a member of the ErbB receptor family.
  • Genes related to growth factor signalling may for example encode for growth factor receptors, growth factor ligands, inhibitors and the like.
  • Genes which meet the above criteria, i.e. that they are correlated and/or coexpressed with a receptor from the ErbB-family or correlated and/or coexpressed with the Progesterone receptor (PGR) status in the said sample are listed in the following table:
  • TABLE 8a
    Genes correlated and/or coexpressed with a receptor
    from the ErbB-family
    Correleated/
    Gene Map Locus coexpressed
    symbol Location Link Genbank ID Unigene_v133_ID with
    LASP1 3927 NM_006148.1 75080 ErbB
    CACNB1 782 NM_000723.1 635 ErbB
    RPL19RPL19 6143 NM_000981.1 252723 ErbB
    PPARGBP 5469 Y13467 15589 ErbB
    CrkRS NM_016507.1 123073 ErbB
    NEUROD2 4761 AB021742.1 322431 ErbB
    MLN64 10948 NM_006804.1 77628 ErbB
    TELETHONIN 8557 NM_003673.1 111110 ErbB
    PNMT 5409 NM_002686.1 1892 ErbB
    ERBB2 2064 X03363.1 323910 ErbB
    GRB7 2886 AB008790.1 86859 ErbB
    PSMD3 5709 NM_002809.1 9736 ErbB
    GCSFG 1440 NM_000759.1 2233 ErbB
    KIAA0130 9862 AI023317 23106 ErbB
    c-erbA-1 X55005 7067 ErbB
    NR1D1 9572 X72631 211606 ErbB
    MLN51 22794 NM_007359.1 83422 ErbB
    CDC6 990 U77949.1 69563 ErbB
    RARA U41742.1 5914 ErbB
    TOP2A 7153 NM_001067.1 156346 ErbB
    IGFBP4 NM_001552.1 1516 ErbB
    CCR7 EBI1 CCR7 NM_001838.1 1652 ErbB
    SMARCE1 6605 NM_003079.1 332848 ErbB
    KRT10 3858 X14487 99936 ErbB
    KRT12 NM_000223.1 66739 ErbB
    hHKa3-II 3884 NM_002279.2 32950 ErbB
    MLLT6 4302 NM_005937 349196 ErbB
    ZNF144 7703 XM_008147 184669 ErbB
    PIP5K2B 8396 NM_138687 432736 ErbB
    TEM7 57125 NM_020405 125036 ErbB
    ZNFN1A3 22806 XM_012694 258579 ErbB
    WIRE 147179 XM_085731 13996 ErbB
    PSMB3 5691 NM_002795 82793 ErbB
    MGC9753 93210 NM_033419 91668 ErbB
    Variant a
    MGC9753 ErbB
    Variant c
    MGC9753 ErbB
    Variant d
    MGC9753 ErbB
    Variant e
    MGC9753 ErbB
    Variant g
    MGC9753 ErbB
    Variant h
    MGC9753 ErbB
    Variant i
    ORMDL3 94103 AF395708 374824 ErbB
    MGC15482 84961 NM_032875 194498 ErbB
    PPP1R1B 84152 NM_032192 286192 ErbB
    MGC14832 84299 NM_032339 333526 ErbB
    LOC51242 51242 NM_057555 12101 ErbB
    FLJ20291 54883 NM_017748 8928 ErbB
    Pro2521 55876 NM_018530 19054 ErbB
    Link-GEFII 51195 NM_016339 118562 ErbB
    CTEN 84951 NM_032865 294022
  • TABLE 8b
    Genes correlated and/or coexpressed with the Progesterone receptor (PGR)
    Correleated/
    Gene Map Locus RefSeq coexpressed
    Symbol Location Link OMIM UniGene Transcript with
    MAPT chr17q21.1 4137 157140 Hs.101174 NM_005910, PGR
    NM_016834,
    NM_016835,
    NM_016841
    MLPH chr2q37.3 79083 606526 Hs.102406 NM_024101 PGR
  • As part of this invention, it was found that tumors demonstrating elevated expression levels of MMP1 and low and/or undetectable MLPH levels belong to the group of “basal-like tumors” exhibiting low expression of ESR1 and Her-2/neu, but yet having a high risk if not treated by chemotherapy regimen.
  • Particularly preferred at least one of the receptors the expression level of which is determined is Her-2/neu.
  • Her-2/neu (also known as ErbB-2, ERBB2) is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. Her-2/neu is notable for its role in the pathogenesis of breast cancer and as a target of treatment. It is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. Her-2/neu is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. However, ErbB receptors dimerize on ligand binding, and Her-2/neu is the preferential dimerization partner of other members of the ErbB family. The Her-2/neu gene is a proto-oncogene located at the long arm of human chromosome 17 (17q11.2-q12).
  • Approximately 25-30 percent of breast cancers, irrespective of whether they are estrogen positive or negative, have an amplification of the Her-2/neu gene or overexpression of its protein product. Overexpression and/or gene amplification of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis.
  • In another preferred embodiment, it is provided that an additional mode of treatment for which prediction is sought is a treatment related to the signalling pathway of a receptor from the ErbB-family, the PDGFR-family and the C-KIT receptor.
  • Such treatment may include the administration of
      • an agonist of a ligand for receptors from the ErbB-family
      • an antagonist, e.g. an antibody or an antibody fragment, against said ligand and/or receptor,
      • an antisense nucleic acid inhibiting the expression of a gene encoding for said ligand and/or receptor,
      • a small molecular drug, and/or
      • a kinase inhibitor specific for the given receptor.
  • By way of illustration and not by way of restriction said agents may be selected from the group consisting of the agents shown in table 9.
  • TABLE 9
    Target Antagonist Kinase inhibitors
    Her-2/neu Herceptin Lapatinib (Tykerb)
    (ErbB-2) (Trastuzumab) GW572016
    Pertuzumab AEE-788
    CI-1033
    PDGFR Gleevec
    Nexavar
    Sutent
    VEGFR Sutent
    Nexavar
    Axitinib
    Pazopanib
    C-KIT Gleevec
    receptor Nexavar
    Sutent
  • Other potential agents may be selected from the group comprising Cetuximab (tradename Erbitux®, target receptor is EGFR), Matuzumab (EMD7200, target receptor is EGFR), Trastuzumab (tradename Herceptin®, target receptor is Her-2/neu), Pertuzumab (target receptor is Her-2/neu), Bevacizumab (tradename Avastin®, target ligand is VEGFA), 2C3 (target ligand is VEGFA), VEGF-trap (AVE-0005, target ligands are VEGFA and PIGF), IMC-1121B (target receptor is VEGFR2), CDP-791 (target receptor is VEGFR2), Gefitinib (tradename Iressa®, ZD-1839, target receptor is EGFR), Erlotinib (tradename Tarceva®, OSI-774, target receptor is EGFR), EKB-569 (target receptor is EGFR), PKI-166 (target receptor is EGFR),), PKI-166 (target receptor is EGFR), Lapatinib (tradename Tycerb®, target receptor is EGFR and Her-2/neu), GW572016 (target receptors are EGFR and Her-2/neu), AEE-788 (target receptors are EGFR, Her-2/neu and VEGFR-2), CI-1033 (target receptors are EGFR, Her-2/neu and Her4), AZD6474 (target receptors are EGFR and VEGFR-2).
  • However, other treatments related to the ErbB receptor family signalling pathway which fall under the scope of the present invention comprise the administration of Sorafenib (tradename Nexavar®, BAY 43-9005, target receptors are VEGFR-2, VEGFR-3, c-KIT, PDGFR-B, RET and Raf-Kinase), BAY 57-9352 (target receptor is VEGFR-2), Sunitinib (tradename Sutent®, target receptors are VEGFR-1, VEGFR-2 and PDGFR), AG13925 (target receptors are VEGFR-1 and VEGFR-2), AG013736 (target receptors are VEGFR-1 and VEGFR-2), AZD2171 (target receptors are VEGFR-1 and VEGFR-2), ZD6474 (target receptors are VEGFR-1, VEGFR-2 and VEGFR-3), Vandetenib (ZD 7646), Vatalanib PTK-787/ZK-222584 (target receptors are VEGFR-1 and VEGFR-2), CEP-7055 (target receptors are VEGFR-1, VEGFR-2 and VEGFR-3), CP-547 (target receptors are VEGFR-1 and VEGFR-2), CP-632 (target receptors are VEGFR-1 and VEGFR-2), GW786024 (target receptors are VEGFR-1, VEGFR-2 and VEGFR-3), AMG706 (target receptors are VEGFR-1, VEGFR-2 and VEGFR-3), Imatinib mesylate (tradename Glivec®/Gleevec®, target receptors are bcr-abl and c-KIT), BMS-214662 (target enzyme is Ras farnesyl transferase), CCI-779 (target enzyme is mTOR), RAD0001 (tradename Everolismus®, target enzyme is mTOR), CI-1040 (target enzyme is MEK), SU6668 (target receptors are VEGFR-2, PDGFR-B and FGFR-1), AZD6126, CP547632 (target receptors are VEGFRs), CP868596 GW786034 (target receptors are PDGFRs), ABT-869 (target receptors are VEGFRs and PDGFRs), AEE788 (target receptors are VEGFRs and PDGFRs), AZD0530 (target enzymes are src and abl), and CEP7055.
  • In this context, other parameters may as well be used and combined in order to predict the therapeutic success for said given mode of treatment. The parameters may be chosen from the group consisting of
      • Menopausal status
      • Overall histological state
      • ECOG performance status
      • Serum Her-2/neu level
      • Serum VEGFA level
      • Serum EGFR level
      • Serum MMP status
      • Serum status of complement factors and its fragments (e.g. C3A)
      • LDH serum levels
  • In yet another preferred embodiment of the present invention, it is provided that said given mode of treatment (a) acts on recruitment of lymphatic vessels, angiogenesis, cell proliferation, cell survival and/or cell motility, and/or b) comprises administration of a chemotherapeutic agent.
  • Furthermore, it is provided in an another preferred embodiment of the present invention that said given mode of treatment comprises, in addition, administration of small molecule inhibitors, antibody based regimen, anti-proliferation regimen, pro-apoptotic regimen, pro-differentiation regimen, radiation and/or surgical therapy.
  • It is particularly preferred that, in the method according to the invention, the said expression level is determined by a) a hybridization based method,
      • b) a PCR-based method, particularly a quantitative real-time PCR method,
      • c) determining the protein level,
      • d) a method based on the electrochemical detection of particular molecules,
      • e) an array based method,
      • f) serial analysis of gene expression (sage), and/or
      • g) a Planar wave guide based method.
  • The above mentioned methods have in common that they are focused on the detection of nucleic acids, particularly on the detection of mRNA, DNA, PNA, LNA and/or Morpholino. Moreover, these methods provide the option to determine more than two agents at the same time (“multiplexing”). Therefore, not only the expression levels of one gene of interest can be determined, but the expression level of many other genes of interest, like other ligands, receptors, oncogenes or metabolism related genes can be determined in order to better characterize a given cancer or neoplastic disease in a patient.
  • In another preferred embodiment of the present invention it is provided that said cancer or neoplastic disease is characterized by a negative Estrogen receptor status, a negative progesterone receptor status and/or a negative Her-2/neu receptor status.
  • Among the different breast cancer subgroups, the group being characterized by negative statuses in all three aspects as mentioned above (also termed “basal tumors”) has the worst prognosis.
  • A proper detection of this group is thus vital to sort out those patients which will draw any benefit from anti estrogen treatment, anti progestereone treatment and/or anti Her-2/neu treatment.
  • A different type of therapy, i.e. neoadjuvant chemotherapy, can thus be administered to these patients, in order to avoid side effects of the above mentioned treatments, and to improve therapy prediction.
  • Furthermore, in a preferred embodiment of the present invention it is provided that said cancer or neoplastic disease is selected from the group consisting of gynaecological cancers including Breast cancer, Ovarian cancer, Cervical cancer, Endometrial cancer, Vulval cancer, and the like.
  • In yet another preferred embodiment of the present invention it is provided that the expression level of at least one of the said gene/s is determined with RT-PCR (reverse transcriptase polymerase chain reaction) of the ligand and/or receptor related mRNA.
  • In another preferred embodiment of the present invention, it is provided that the expression level of at least one of the said gene/s is determined in formalin and/or paraffin fixed tissue samples.
  • In yet another preferred embodiment of the present invention, it is provided that the expression level of at least one of the said gene/s is determined in serum, plasma or whole blood samples.
  • Routinely, in tumor diagnosis tissue samples are taken as biopsies form a patient and undergo diagnostic procedures. For this purpose, the samples are fixed in formalin and/or paraffin and are then examined with immunohistochemistry methods. The formalin treatment leads to the inactivation of enzymes, as for example the ubiquitous RNA-digesting enzymes (RNAses). For this reason, the mRNA status of the tissue (the so called transcriptome), remains unaffected.
  • However, the formalin treatment leads to partial depolymerization of the individual mRNA molecules. For this reason, the current doctrine is that formalin fixed tissue samples can not be used for the analysis of the transcriptome of said tissue.
  • For this reason, it is provided in a preferred embodiment of the present invention that after lysis, the samples are treated with silica-coated magnetic particles and a chaotropic salt, in order to purify the nucleic acids contained in said sample for further determination.
  • Collaborators of the inventors of the present invention have developed an approach which however allows successful purification of mRNA out of tissue samples fixed in such manner, and which is disclosed, among others, in WO03058649, WO2006136314A1 and DE10201084A1, the content of which is incorporated herein by reference.
  • Said method comprises the use of magnetic particles coated with silica (SiO2). The silica layer is closed and tight and is characterized by having an extremely small thickness on the scale of a few nanometers. These particles are produced by an improved method that leads to a product having a closed silica layer and thus entail a highly improved purity. The said method prevents an uncontrolled formation of aggregates and clusters of silicates on the magnetite surface whereby positively influencing the additional cited properties and biological applications. The said magnetic particles exhibit an optimized magnetization and suspension behavior as well as a very advantageous run-off behavior from plastic surfaces. These highly pure magnetic particles coated with silicon dioxide are used for isolating nucleic acids, including DNA and RNA, from cell and tissue samples, the separating out from a sample matrix ensuing by means of magnetic fields. These particles are particularly well-suited for the automatic purification of nucleic acids, mostly from biological body samples for the purpose of detecting them with different amplification methods.
  • The selective binding of these nucleic acids to the surface of said particles is due to the affinity of negatively charged nucleic acids to silica containing media in the presence of chaotropic salts like guanidinisothiocyanate. Said binding properties are known as the so called “boom principle”. They are described in the European patent EP819696, the content of which is incorporated herein by reference.
  • The said approach is particularly useful for the purification of mRNA out of formalin and/or paraffin fixed tissue samples. In contrast to most other approaches, which leave very small fragments behind that are not suitable for later determination by PCR and/or hybridization technologies, the said approach creates mRNA fragments which are large enough to allow specific primer hybridization and/or specific probe hybridization. A minimal size of at least 100 bp, more preferably 200 base pairs is needed for specific and robust detection of target gene expression. Moreover it is also necessary to not have too many inter-sample variations with regard to the size of the RNA fragments to guarantee comparability of gene expression results. Other issues of perturbance of expression data by sample preparation problems relate to the contamination level with DNA, which is lower compared to other bead based technologies. This of particular importance, as the inventors have observed, that DNAse treatment is not efficient in approximately 10% of FFPE samples generated by standard procedures and stored at room temperature for some years before cutting and RNA extraction.
  • The said approach thus allows a highly specific determination of candidate gene expression levels with one of the above introduced methods, particularly with hybridization based methods, PCR based methods and/or array based methods, even in formalin and/or paraffin fixed tissue samples, and is thus extremely beneficial in the context of the present invention, as it allows the use of tissue samples fixed with formalin and paraffin, which are available in tissue banks and connected to clinical databases of sufficient follow-up to allow retrospective analysis.
  • Furthermore, a kit useful for carrying out one of the said methods is provided, said kit comprising at least
      • a) a primer pair and/or a probe each having a sequence sufficiently complementary to at least one gene according to the invention, and/or
      • b) an antibody directed against an expression product related to at least one gene according to the invention.
  • In yet another embodiment of the invention a method for correlating the clinical outcome of a patient suffering from or at risk of developing a neoplastic disease is provided, said method comprising the steps of:
      • a) obtaining a fixed biological sample from said patient;
      • b) determining the expression level of at least one gene of interest in said sample according to any of the above methods, and
      • c) correlating the pattern of expression levels determined in (b) with said patient's data, said data being selected from the group consisting of etiopathology data, clinical symptoms, anamnesis data and/or data concerning the therapeutic regimen.
  • The said method is particularly beneficial for epidemiological studies. These studies profit from the fact that large tissue databases exist comprising paraffin and/or formalin fixed tissue samples together with an extensive documentation of the patient's history, including etiopathology data, clinical symptoms, anamnesis data and/or data concerning the therapeutic regimen.
  • The said methods allows for large scale studies which comprise the correlation of the clinical outcome of a patient suffering from or at risk of developing a neoplastic disease with a negative or a positive Estrogen receptor status. In order to successfully adopt this approach, the above introduced method for mRNA purification comprising silica coated magnetic beads and chaotropic salts is quite helpful.
  • Furthermore, the present invention provides a nucleic acid molecule, selected from the group consisting of
      • a) the nucleic acid molecule presented as SEQ ID NO:1-28;
      • b) a nucleic acid molecule having a length of 4-80 nucleotides, preferably 18-30 nucleotides, the sequence of which corresponds to the sequence of a single stranded fragment of a gene encoding for a ligand and/or receptor selected from the group consisting of ESR1, ESR2, PGR, EGFR, Her-2/neu, ERBB3, ERBB4, MLPH, MMP1, MMP7, MMP9, MMP11, MMP10, MMP13 and immune genes such as IGHM, IGHG, IGHD, IGLC, IGLJ, IGLL, IGLV;
      • c) a nucleic acid molecule that is a fraction, variant, homologue, derivative, or fragment of the nucleic acid molecule presented as SEQ ID NO: 1-28;
      • d) a nucleic acid molecule that is capable of hybridizing to any of the nucleic acid molecules of a)-c) under stringent conditions;
      • e) a nucleic acid molecule that is capable of hybridizing to the complement of any of the nucleic acid molecules of a)-d) under stringent conditions;
      • f) a nucleic acid molecule that is capable of hybridizing to the complement of a nucleic acid molecule of e);
      • g) a nucleic acid molecule having a sequence identity of at least 95% with any of the nucleic acid molecules of a)-f);
      • h) a nucleic acid molecule having a sequence identity of at least 70% with any of the nucleic acid molecules of a)-f);
      • i) a complement of any of the nucleic acid molecules of a)-h), or
      • j) a nucleic acid molecule that comprises any nucleic acid molecule of a)-i).
  • See table 12 for a sequence listing. These nucleic acids are being used either as primers for a polymerase chain reaction protocol, or as detectable probes for monitoring the said process.
  • Furthermore it is provided that the said nucleic acid is selected from the group consisting of DNA, RNA, PNA, LNA and/or Morpholino. The nucleic acid may, in a preferred embodiment, be labelled with at least one detectable marker. This feature is applicable particularly for those nucleic acids which serve as detectable probes for monitoring the polymerase chain reaction process.
  • Such detectable markers may for example comprise at least one label selected from the group consisting of fluorescent molecules, luminescent molecules, radioactive molecules, enzymatic molecules and/or quenching molecules.
  • In a particularly preferred embodiment, the said detectable probes are labeled with a fluorescent marker at one end and a quencher of fluorescence at the opposite end of the probe. The close proximity of the reporter to the quencher prevents detection of its fluorescence; breakdown of the probe by the 5′ to 3′ exonuclease activity of the taq polymerase breaks the reporter-quencher proximity and thus allows unquenched emission of fluorescence, which can be detected. An increase in the product targeted by the reporter probe at each PCR cycle therefore causes a proportional increase in fluorescence due to the breakdown of the probe and release of the reporter.
  • In another preferred embodiment of the present invention, a kit of primers and/or detection probes is provided, comprising at least one of the nucleic acids according to the above enumeration and/or their fractions, variants, homologues, derivatives, fragments, complements, hybridizing counterparts, or molecules sharing a sequence identity of at least 70%, preferably 95%.
  • Said kit may, in another preferred embodiment, comprise at least one of the nucleic acid molecules presented as SEQ ID NO: 1-28, and/or their fractions, variants, homologues, derivatives, fragments, complements, hybridizing counterparts, or molecules sharing a sequence identity of at least 70%, preferably 95%, for the detection of at least one gene of interest.
  • Furthermore, the use of a nucleic acid according as recited above, or of a kit as recited above for the prediction of a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards a given mode of treatment.
    • Disclaimer
  • To provide a comprehensive disclosure without unduly lengthening the specification, the applicant hereby incorporates by reference each of the patents and patent applications referenced above.
  • The particular combinations of elements and features in the above detailed embodiments are exemplary only; the interchanging and substitution of these teachings with other teachings in this and the patents/applications incorporated by reference are also expressly contemplated. As those skilled in the art will recognize, variations, modifications, and other implementations of what is described herein can occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention as claimed. Accordingly, the foregoing description is by way of example only and is not intended as limiting. The invention's scope is defined in the following claims and the equivalents thereto. Furthermore, reference signs used in the description and claims do not limit the scope of the invention as claimed.
    • BRIEF DESCRIPTION OF THE EXAMPLES AND DRAWINGS
  • Additional details, features, characteristics and advantages of the object of the invention are disclosed in the subclaims, and the following description of the respective figures and examples, which, in an exemplary fashion, show preferred embodiments of the present invention. However, these drawings should by no means be understood as to limit the scope of the invention.
    • Example 1
  • Core needle biopsy specimen of breast tumors, which had been formalin fixed (FFPE tissues) or were available as fresh tissues were analyzed. Formalin fixed tissues were available from breast cancer patients (≥cT2, NO/N1, MO) receiving neoadjuvant chemotherapy of 4 cycles of epirubicin and cyclophosphamide (90/600 mg/m2) followed by 4 cycles paclitaxel (175 mg/m2). Trastuzumab was administered parallel to paclitaxel therapy on a three weekly dose (6 mg/kg) and continued for 33 weeks after surgery (according to the TECHNO trial) if tumors were IHC positive (e.g DAKO status 3 with intense and continuous membrane staining) or FISH positive (e.g. >2.1 gene copies of Her-2/neu gene per nucleus). Patients with Her-2/neu negative tumors (equally to IHCl+ or FISH negative testing) were not treated with trastuzumab (PREPARE trial). The Her-2/neu status was determined in core-needle biopsies of all patients by immunohistochemistry or FISH analysis at a central reference pathology department. In total 853 Paraffin embedded core needle biopsies were used for analysis. In addition, 86 fresh tissue specimen were used from breast cancer patients ((cT1-4, N0/N1, MO) receiving neoadjuvant chemotherapy of 4 to 6 cycles of epirubicin and cydophosphamide (90/600 mg/m2) 14 days apart. The samples were flash-frozen and analyzed by microarrays.
  • Analysis of MMP genes (in particular MMP7), MLPH, Keratins (in particular Keratin 5) and genes related to the Immune System such as the immunoglobulin gene family (e.g. IGHM, IGHG, IGHD, IGLC, IGLJ, IGLL, IGLV and the like were informative and did predict response to neoadjuvant chemotherapy.
  • Combinatorial analysis of genes such as MMP7, Keratin 5, MLPH and IGHM status on the RNA level were possible and meaningful in fresh tissue specimen by commercially available Affymetrix GeneArrays and in FFPE tissues from core needle biopsies despite highly variable tumor contents. Overall there was a good correlation between the different IHC, FlSH and qPGR methods for standard markers such as ESR1 and Her-2/neu, although the tumor cell content of the tissues varied substantially with 46% of the tumors having a tumor cell content of >50% and 16% of the tumors having less than 20% tumor cells (median 40%).
    • Example 2
  • The determination of high MMP7 and low MLPH and Her-2/neu expression levels identified a population of breast tumors having a particularly good response to chemotherapy. By this combined analysis we could identify a subpopulation of ESR1 negative tumors that drew benefit from neoadjuvant treatment consisting of an anthracyclin and cyclophosphamid and therefore could be spared from additional regimen (such as Taxol).
    • Example 3
  • A group of patients was treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs. E-T-CMF) in the context of a randomized Phase III study. RNA was isolated from 217 fixed tumor tissue samples employing an experimental method based on magnetic beads from Siemens Medical Solutions Diagnostics, followed by kinetic one-step RT-PCR for mRNA expression analysis. Identification of molecular subtypes was based on 2D hierarchical clustering of four genes. One of these genes (melanophilin, MLPH) is known to be associated with ESR1-positive tumors only.
  • The hierarchical clustering based on ESR, PGR, Her-2/neu, and MLPH mRNA expression resulted into 6 identifiable groups, i.e.
      • 1=ESR and PGR positive
      • 5=ESR and Her-2/neu positive
      • 4=ESR less positive and PGR negative
      • 6=Basal Like with some ESR and Her-2/neu activity left
      • 2=Her-2/neu positive and ESR negative
      • 3=Basal like with lowest ESR and PGR activity
  • See FIG. 2 for an illustration. Furthermore, two groups (groups 6 and 3) of low (basal-like, 14+18=32 of 217, 15%) and two groups (1 and 5) of high (86 of 217, 40%) mRNA expression were identified.
  • Patients with basal-like tumors (i.e. groups 6 and 3) were found to have significantly shorter overall survival (p=0.02) compared to the patients with high mRNA expression. No difference was found in terms of disease-free survival (p=0.373) (see FIGS. 3 and 4). Interestingly, survival of basal-like patients appears to reach a plateau after the 5th year, with neither recurrences nor deaths being observed during an additional 4 years of follow-up.
  • The results of this study confirm that basal-like patients, identified by only four genes among high-risk breast cancer patients, have a poor prognosis. Confirmation studies are currently being performed by evaluating specific basal-like genes.
  • It is worth mentioning that the above analysis has been carried out
      • on the basis of the determination of the expression level of four genes only (alternatively, genes can be determined which are coexpressed with any of these genes), and
      • on the basis of Formalin-Fixed Paraffin-Embedded Tissue.
  • Methods according to the state of the art (as disclosed in Sorlie et al., 2001) require the analysis of more than 500 genes, and the use of fresh tissue. While the first advantage is due to intelligent test design, the later is due to use of the Siemens Proprietary magnetic bead technology (see claim XX and discussion).
    • Example 4
  • In order to investigate possible differential EGF and VEGF receptor mRNA expression in the two basal-like subtypes described in Example 3, the following experiment was carried out.
  • Patients were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs. E-T-CMF) in the context of a randomized Phase III study. RNA was isolated from 217 fixed tumor tissue samples, followed by kinetic one-step RT-PCR for mRNA expression analysis of EGFR, VEGFR2 and VEGFR3. Identification of the basal-like subtypes was based on 2D hierarchical clustering.
  • One of the basal-like subtypes (14 of 217 patients, 6%, group 6 of Example 3) was found to retain some expression of the Her-2/neu, ESR and MLPH genes.
  • The second basal-like subtype (18 of 217 patients, 8%, group 3 of Example 3) was characterized by low mRNA expression of all four genes. Significantly more patients in group 6 exhibited high VEGFR2 and VEGFR3 mRNA expression compared to group 3 (Fisher's exact test, p=0.026 and p=0.025, respectively).
  • Patients being thus characterised might therefore receive benefit from anti VEGF-therapy, for example with sunitinib (Sutent), sorafenib (Nexavar), axitinib, and pazopanib.
  • In contrast, no such difference was observed for EGFR mRNA expression, i.e. both groups featured a relatively high EGFR gene expression. This means that significantly more patients in the two basal-like subtypes exhibited high EGFR mRNA expression compared to a group of non-basal-like patients (86 of 217, 40%) exhibiting high mRNA expression of all four genes (p<0.0001).
  • The results of this retrospective study suggest that patients from both basal-like subtypes may be candidates for new anti-EGFR agents. However, agents targeting the VEGF receptor family may only be active in the subgroup of basal-like patients retaining some expression of the Her-2, ESR and MLPH genes (group 6).
    • Example 5
  • Further analysis revealed that in tumors of group 3 the gene Birc5 (survivin) is highly expressed (no data shown). This gene has the following specification
  • TABLE 10
    Survivin gene
    Gene Map Locus RefSeq
    Symbol Location Link OMIM UniGene Transcript
    BIRC5 chr17q25 603352 Hs.514527
  • Survivin is a member of inhibitors of apoptosis (IAPB) family, which are upregulated in various malignancies. It has been described that high survivin expression is associated with favorable outcome of some carcinomas after radiation therapy (Freier et al. (2007).
  • This means that group 3 tumors, while not likely to be affected by anti VEGF therapy, might be susceptible to radiation therapy.
  • It is worth to be mentioned that a differentiation of the two basal-like subtypes (i.e. groups 3 and 6) has for the first time been described here.
  • Sor far, basal-like subtype tumors were classified as high-risk breast cancer patients, associated with poor prognosis. The differentiation as described above opens new ways to provide a more specific therapy to the patients affected, i.e. anti VEGF therapy (for group 6) or radiotherapy (for group 3). This has so far not been possible.
    • FIG. 1
  • The inventors have further analyzed said genes in breast carcinomas treated with neoadjuvant chemotherapeutic treatments (e.g. EC, EC-T, TAC) to analyze whether these tumors do respond to chemotherapeutic regimen. These analysis were done by Affymetrix array analysis (HG U133A) in fresh tissue biopsies or RT-kPCR analysis in fixed tissue biopsies of high risk breast tumors. It was found that >60% of these tumors do respond to chemotherapeutic regimen by pathological complete response, meaning no tumor is left after chemotherapeutic regimen in the primary tumor site or in the lymphnodes. This reflects a more that 4 fold higher response rate in this subgroup of patients compared to the unstratified cohort which refelected an approximately 15% pCR rate. 50% of all pathological complete responding breast tumors were within this subgroup of patients, which refelected approximately 15% of all patients. Breast tumors exhibiting a pathological complete response after chemotherapeutic treatment exhibit a good prognosis.
  • In addition, if tumors were further selected on basis of high immune marker expression, such as IGHM expression levels, approximately 90% of the tumors having high MMP7 and low MLPH level exhibited pathological complete response as depicted in FIG. 2.
  • Hormonal receptor status and Her-2/neu over-expression are important prognostic variables in patients with operable breast cancer. The majority of basal-like tumors are triple-negative for estrogen receptors (ESR), progesterone (PGR) and Her-2/neu receptors. Such tumors are found in approximately 120 of breast cancer patients and have been shown to have a poor prognosis.
    • FIG. 2
  • FIG. 2 shows identification of the basal-like subtypes based on 2D hierarchical clustering, as described in Example 3. Green indicates low gene expression, whereas red indicates high gene expression The Molecular classification was based on only four genes (estrogen receptors (ESR), progesterone receptors (PGR), Her-2/neu, and melanophilin (MLPH).
  • The analysis revealed the following tumor types:
      • 1=ESR and PGR positive
      • 5=ESR and Her-2/neu positive
      • 4=ESR less positive and PGR negative
      • 6=Basal Like with some ESR and Her-2/neu activity left
      • 2=Her-2/neu positive and ESR negative
      • 3=Basal like with lowest ESR and PGR activity
  • The following table gives an overview about the different groups and potential therapeutic approaches:
  • TABLE 11a
    Tumor groups classifiable with the method according
    to the invention, and possible therapies
    Marker status/
    Group expression level Tumor status Therapy approach
    1 ESR and PGR ESR positive Endocrine therapy,
    positive i.e. tamoxifen
    5 ESR and Her-2/neu ESR positive Endocrine therapy
    positive, PGR on a in combination with
    medium level anti-ErbB therapy
    (i.e. trastuzumab)
    4 ESR on a medium
    level, PGR negative,
    Her-2/neu
    6 some residual ESR “triple negative”, anti VEGF therapy
    and Her-2/neu activity Basal like Tumor (i.e. Nexavar);
    left, PGR negative optionally: new
    anti-ErbB therapy
    2 Her-2/neu positive anti ErbB therapy
    and ESR negative (i.e. trastuzumab)
    3 ESR and PGR almost “triple negative”, anti VEGF therapy
    zero, some residual Basal like Tumor (i.e. Nexavar);
    Her-2/neu activity left Birc5 (survivin) optionally: new
    high anti-ErbB therapy.
    Radiotherapy due to
    coexpression
    of Birc5
  • Furthermore, as mentioned above, groups 3 and 6 can be further specified with respect to their CCND, BRCA1 and RB1 status, namely by means of detecting the MMP7 and/or MLPH status. This in turn may open up complementary therapeutic approaches:
  • TABLE 11b
    Tumor groups classifiable with another method
    according to the invention, and possible therapies
    Marker status/
    Group expression level Tumor status Therapy approach
    3 or 6 MMP7 positive CCND negative inhibition of
    and/or RB1 negative homologous
    MLPH positive BRCA1 negative recombination repair
    (e.g. PARP1
    inhibition)
    • FIGS. 3 and 4
  • FIGS. 3 and 4 show Kaplan Meyer curves in which, for the different groups determined as above (see Example 3), the overall survival time (OAS) is plotted versus the respective percentage. It is obvious that the basal-like subtypes (groups 6 and 3) have the worst survival rates, and are thus associated with poor prognosis. For this reason, it is vital that the method according to the invention provides a method to detect these subtypes, in order to submit the respective patients to different and/or novel treatments.
  • Appendix:
    Primer sequences
    TABLE 12:
    Primer sequences and probe sequences used in
    accordance with the present invention
    SEQ
    ID
    NO: Gene PCR probe Forward primer Reverse primer
     1-3 ERBB2 AGGCCAAGTCCGC TCTGGACGTGCCAG CCTGCTCCCTGAGGA
    Her- AGAAGCCCT TGTGAA CACAT
    2/neu
     4-6 ERBB2 ACCAGGACCCACC CCAGCCTTCGACAA TGCCGTAGGTGTCCC
    Her- AGAGCGGG CCTCTATT TTTG
    2/neu
     7-9 ERBB2 TGATCATGGTCAA CCATCTGCACCATT CGGAATCTTGGCCGA
    Her- ATGTTGGATGATT GATGTCTAC CATT
    2/neu GACTC
     9-12 ERBB2 AAGATTCCCCTTC ACGCCCTCAGAAGA TGTGCTGACGCAAGC
    Her- TTCCTGGGA TTGGAA TACAAC
    2/neu
    13-15 MLPH CCAGCAGGCAGAG GCAGTGACGGCCTC CTGCAATCCTGGATT
    AGCGAGGTTTC AGAAG CAATGTC
    16-18 MLPH CCAAATGCAGACC TCGAGTGGCTGGGA AGATAGGGCACAGCC
    CTTCAAGTGAGGC AACTTG ATTGC
    19-21 MLPH CGGGCGTCTTCTG CGATGTGGACACCT AGGCATTCCACAGCT
    AGAGTCAGATCTT CTGATGA GAAATATG
    TG
    22-24 MMP7 CAGTCTAGGGATT GAACGCTGGACGGA GAATGGCCAAGTTCA
    AACTTCCTGTATG TGGTA TGAGTTG
    CT
    25-28 MMP7 AGTGGGAACAGGC CGGGAGGCATGAGT GGCATTTTTTGTTTC
    TCAGGACTATCTC GAGCTA TGAGTCATAGA
    AAGAG
    • LIST OF REFERENCES
    • Freier et al., Int. J. Cancer Volume 120, Issue 4, Pages 942-946 (2007)
    • Faneyte et al., British Journal of Cancer 88, 406-412 (2003)
    • Ring et al., Endocr Relat Cancer 11: 643-658 (2004)
    • Sorlie et al., PNAS 98(19): 10869-74 (2001)

Claims (21)

What is claimed is:
1. A method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of:
a) obtaining a biological sample from said patient;
b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample,
c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and
d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c).
2. The method according to claim 1, characterized in that the at least one gene of interest is correlated with a negative Estrogen receptor status.
3. The method of claim 1, characterized in that the at least one gene of interest may be assigned to at least one biological motif selected from the group consisting of
extracellular matrix degradation,
growth factor signaling,
immune cell infiltration, and/or
basal markers.
4. The method of claim 1, characterized in that the method further comprises the steps of
e) determining the expression level of at least one gene correlated and/or coexpressed with a receptor from the ErbB-family in the said sample, and/or
f) determining the expression level of at least one gene correlated and/or coexpressed with the Progesteron receptor (PGR) status in the said sample.
5. The method according to claim 4, characterized in that the gene of interest the expression level of which is determined is selected from the group comprising Her-2/neu(=ErbB), MMP7, MMP1, PGR, ESR1, MLPH, IGHM, C-Kit, C-MET and/or EGFR.
6. The method of claim 1, characterized in that at least one mode of treatment for which prediction is sought is a neoadjuvant chemotherapy, a targeted therapy and/or a therapy directed to the inhibition of homologous recombination repair.
7. The method of claim 1, characterized in that an additional mode of treatment for which prediction is sought is a treatment related to the signalling pathway of a receptor from the ErbB-family.
8. The method of claim 1, wherein the expression level is determined by
a) a hybridization based method,
b) a PCR-based method, particularly a quantitative real-time PCR method,
c) determining the protein level,
d) a method based on the electrochemical detection of particular molecules,
e) an array based method,
f) serial analysis of gene expression (sage) and/or
g) a Planar wave guide based method.
9. The method of claim 1, characterized in that said cancer or neoplastic disease is characterized by a negative Estrogen receptor status, a negative progesterone receptor status and/or a negative Her-2/neu receptor status.
10. The method of claim 1, characterized in that said cancer or neoplastic disease is selected from the group consisting of gynaecological cancers including Breast cancer, Ovarian cancer, Cervical cancer, Endometrial cancer, and/or Vulval cancer.
11. The method of claim 1, characterized in that the expression level of at least one of the said genes is determined with rtPCR (reverse transcriptase polymerase chain reaction) of the gene-related mRNA.
12. The method of claim 1, characterized in that the expression level of at least one of the said ligands of is determined in formalin and/or paraffin fixed tissue samples.
13. The method claim 1, wherein, after lysis, the samples are treated with silica-coated magnetic particles and a chaotropic salt, in order to purify the nucleic acids contained in said sample for further determination.
14. A kit, comprising at least
a) a primer pair and/or a probe each having a sequence sufficiently complementary to at least one gene as set forth in any of the aforementioned claims, and/or
b) an antibody directed against an expression product related to at least one gene as set forth in any of the aforementioned claims
15. A method for correlating the clinical outcome of a patient suffering from or at risk of developing a neoplastic disease, said method comprising the steps of:
a) obtaining a fixed biological sample from said patient;
b) determining the expression level of at least one gene of interest in said sample according to any of the above methods, and
c) correlating the pattern of expression levels determined in (b) with said patient's data, said data being selected from the group consisting of etiopathology data, clinical symptoms, anamnesis data and/or data concerning the therapeutic regimen.
16. A nucleic acid molecule, selected from the group consisting of
a) the nucleic acid molecule presented as SEQ ID NO:1-28
b) a nucleic acid molecule having a length of 4-80 nucleotides, preferably 18-30 nucleotides, the sequence of which corresponds to the sequence of a single stranded fragment of a gene encoding for a ligand and/or receptor selected from the group consisting of ESR1, ESR2, PGR, EGFR, Her-2/neu, ERBB3, ERBB4, MLPH, MMP1, MMP7, MMP9, MMP11, MMP10, MMP13 and immune genes such as IGHM, IGHM, IGHG, IGHD, IGLC, IGLJ, IGLL, IGLV;
c) a nucleic acid molecule that is a fraction, variant, homologue, derivative, or fragment of the nucleic acid molecule presented as SEQ ID NO: 1-28;
d) a nucleic acid molecule that is capable of hybridizing to any of the nucleic acid molecules of a)-c) under stringent conditions;
e) a nucleic acid molecule that is capable of hybridizing to the complement of any of the nucleic acid molecules of a)-d) under stringent conditions;
f) a nucleic acid molecule that is capable of hybridizing to the complement of a nucleic acid molecule of e)
g) a nucleic acid molecule having a sequence identity of at least 95% with any of the nucleic acid molecules of a)-f);
h) a nucleic acid molecule having a sequence identity of at least 70% with any of the nucleic acid molecules of a)-f);
i) a complement of any of the nucleic acid molecules of a)-h), or
j) a nucleic acid molecule that comprises any nucleic acid molecule of a)-i).
17. The nucleic acid according to claim 16, characterized in that the said nucleic acid is selected from the group consisting of DNA, RNA, PNA, LNA and/or Morpholino.
18. The nucleic acid of claim 16, characterized in that it is labelled with at least one detectable marker.
19. A kit of primers and/or detection probes, comprising at least one of the nucleic acids of claim 16 and/or their fractions, variants, homologues, derivatives, fragments, complements, hybridizing counterparts, or molecules sharing a sequence identity of at least 70%, preferably 95%.
20. The kit according to claim 19, comprising at least one of the nucleic acid molecules presented as SEQ ID NO: 1-28 and/or their fractions, variants, homologues, derivatives, fragments, complements, hybridizing counterparts, or molecules sharing a sequence identity of at least 70%, preferably 95%, for the detection of at least one gene of interest.
21. (canceled)
US15/913,563 2007-11-30 2018-03-06 Method For Predicting Therapy Responsiveness In Basal Like Tumors Abandoned US20180251854A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/913,563 US20180251854A1 (en) 2007-11-30 2018-03-06 Method For Predicting Therapy Responsiveness In Basal Like Tumors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US99139107P 2007-11-30 2007-11-30
EP08100606.6 2008-01-17
EP08100606 2008-01-17
PCT/EP2008/065040 WO2009068423A2 (en) 2007-11-30 2008-11-06 Method for predicting therapy responsiveness in basal like tumors
US12/745,668 US9932639B2 (en) 2007-11-30 2008-11-06 Method for predicting therapy responsiveness in basal like tumors
US15/913,563 US20180251854A1 (en) 2007-11-30 2018-03-06 Method For Predicting Therapy Responsiveness In Basal Like Tumors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US12/745,668 Division US9932639B2 (en) 2007-11-30 2008-11-06 Method for predicting therapy responsiveness in basal like tumors
PCT/EP2008/065040 Division WO2009068423A2 (en) 2007-11-30 2008-11-06 Method for predicting therapy responsiveness in basal like tumors

Publications (1)

Publication Number Publication Date
US20180251854A1 true US20180251854A1 (en) 2018-09-06

Family

ID=40279040

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/745,668 Active 2031-01-01 US9932639B2 (en) 2007-11-30 2008-11-06 Method for predicting therapy responsiveness in basal like tumors
US15/913,563 Abandoned US20180251854A1 (en) 2007-11-30 2018-03-06 Method For Predicting Therapy Responsiveness In Basal Like Tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/745,668 Active 2031-01-01 US9932639B2 (en) 2007-11-30 2008-11-06 Method for predicting therapy responsiveness in basal like tumors

Country Status (3)

Country Link
US (2) US9932639B2 (en)
EP (1) EP2215251A2 (en)
WO (1) WO2009068423A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
MX338883B (en) 2010-07-27 2016-05-04 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer.
WO2014165855A1 (en) * 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CN111500719B (en) * 2020-03-24 2022-06-07 中国辐射防护研究院 Use of IGHMBP2 gene as molecular marker for predicting radiation sensitivity
CN111334578A (en) * 2020-03-24 2020-06-26 中国辐射防护研究院 IGHMBP2 gene mutation site detection kit and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8900725A (en) 1989-03-23 1990-10-16 Az Univ Amsterdam METHOD AND COMBINATION OF AGENTS FOR INSULATING NUCLEIC ACID.
DE10058394C1 (en) 2000-11-24 2002-07-11 Siemens Ag Methods for biochemical analysis and associated arrangement
DE10058397A1 (en) 2000-11-24 2002-06-06 Siemens Ag Arrangement for an electrochemical analysis method and its use
DE10126341A1 (en) 2001-05-30 2002-12-12 Siemens Ag Electrochemical DNA sensor, method for producing and operating such a DNA sensor
DE10201084A1 (en) 2002-01-14 2003-07-24 Bayer Ag Magnetic particles containing silicon, process for their production and use of the particles
EP2799555B1 (en) 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
JP2005524399A (en) 2002-05-03 2005-08-18 レイヴェン バイオテクノロジーズ， インコーポレイテッド ALCAM and ALCAM modulators
CA2574447A1 (en) * 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
ATE550440T1 (en) 2004-11-05 2012-04-15 Genomic Health Inc MOLECULAR INDICATORS FOR BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
CN101213619A (en) 2005-06-23 2008-07-02 西门子医疗系统诊断股份有限公司 Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use
EP1949152A4 (en) 2005-11-14 2014-02-05 Bayer Ip Gmbh Planar waveguide detection chips and chambers for performing multiplex pcr assays
WO2007142987A2 (en) 2006-05-30 2007-12-13 Wisconsin Alumni Research Foundation Mammary stem cell marker
US20100087330A1 (en) * 2007-01-26 2010-04-08 Brian Leyland-Jones Breast cancer gene array

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ariazi et al (Mol Cancer Res 2007; Vol 5 No. 1, January 2007, pages 71-85). (Year: 2007) *
Choi et al in "A Comparison of Five Immunohistochemical Biomarkers and HER-2/neu Gene Amplification by Fluorescence In Situ Hybridization in White and Korean Patients with Early-Onset Breast Carcinoma" (Cancer, October 15, 2003, Vol 98, No. 8, pages 1587-1595). (Year: 2003) *

Also Published As

Publication number Publication date
EP2215251A2 (en) 2010-08-11
WO2009068423A2 (en) 2009-06-04
US20110118129A1 (en) 2011-05-19
WO2009068423A3 (en) 2009-07-16
US9932639B2 (en) 2018-04-03

Similar Documents

Publication Publication Date Title
EP2390370B1 (en) A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
US20180251854A1 (en) Method For Predicting Therapy Responsiveness In Basal Like Tumors
Agell et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression
JP2008521412A (en) Lung cancer prognosis judging means
US20120015827A1 (en) Method for therapy prediction in tumors having irregularities in the expression of at least one vegf ligand and/or at least one erbb-receptor
WO2010076322A1 (en) Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
US20160355889A1 (en) Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
US20110165566A1 (en) Methods of optimizing treatment of breast cancer
US20130143753A1 (en) Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
US20130267440A1 (en) Marker for carcinoma
EP2281063B1 (en) A method for predicting a clinical response of a patient suffering from or at risk of developing cancer towards a given mode of treatment
EP2065399A1 (en) The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy
WO2009068409A1 (en) A method to assess prognosis and to predict therapeutic response to endocrine treatment
EP2065473A1 (en) A method to assess prognosis and to predict therapeutic success in gynecologic cancer
US20140086911A1 (en) Methods and Products for Predicting CMTC Class and Prognosis in Breast Cancer Patients
WO2010003772A1 (en) Method for predicting adverse response to erythropoietin in breast cancer treatment
EP2138589A1 (en) Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen
US20160273045A1 (en) Methods of determining breast cancer prognosis
Doherty et al. Gene expression in normal urothelium depends on location within the bladder: a possible link to bladder carcinogenesis
EP2034027A1 (en) Molecular markers to predict response to chemotherapy and EGFR family inhibiton by targeted strategies

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION